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TRANSFORMING GROWTH FACTOR-BETA (TGFß)-MEDIATED POSTTRANSCRIPTIONAL REGULATION OF EPITHELIAL-MESENCHYMAL
TRANSDIFFERENTIATION (EMT)
ARINDAM CHAUDHURY
ABSTRACT
TGFβ

induces

epithelial-mesenchymal

transdifferentiation

(EMT)

accompanied by cellular differentiation and migration, a process fundamental
during embryonic development and one that is reactivated in a variety of
diseases including fibrosis and cancer. Despite extensive transcriptomic profiling,
identification of TGFβ-inducible, EMT-specific genes has met with limited
success. Here, we report a novel post-transcriptional pathway by which TGFβ
modulates expression of EMT-specific proteins and EMT itself. We show that
heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) binds a structural, 33
nucleotides (nt) TGF-beta-activated translation (BAT) element in the 3’untranslated regions (UTRs) of disabled-2 (Dab2) and interleukin-like EMT
inducer (ILEI) transcripts, and repress their translation. TGFβ activation leads to
phosphorylation at Ser43 of hnRNP E1 by protein kinase Bβ/Akt2, inducing its
release from the BAT element and reversal of translational silencing of Dab2 and
ILEI mRNAs. Further, using a genome-wide combinatorial approach involving

viii

polysome profiling and RIP-Chip analyses we have identified a cohort of four
mRNAs (Rhox5, Ube3A, Prl2c4 and IL-11Rα2) that follow the same pattern of
regulation as Dab2 and ILEI. Each of the identified targets mRNA harbors a
functional BAT element in the 3’-UTR and is required for TGFβ-induced EMT.
Modulation of hnRNP E1 expression or its post-translational modification alters
TGFβ-mediated translational activation of the target transcripts and EMT in vitro
and in vivo. This cohort of mRNAs may represent a new TGFβ responsive and
hnRNP E1-mediated posttranscriptional regulon that regulates TGFβ-induced
EMT during development and metastatic progression of tumors in a temporal and
expedited fashion. The autocrine response of cells to TGFβ-induced Akt2
activation and subsequent translational activation of EMT inducer transcripts may
represent a novel mechanism through which the increased TGFβ expression in
tumor cells contributes to cancer progression.
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CHAPTER I
INTRODUCTION

1.1. Transforming Growth Factor-beta (TGFβ)
TGFβ is a pleiotropic cytokine that is secreted by fibroblasts and epithelial
cells in a tissue specific manner and functions in a context-dependent fashion. In
the 1970s, a host of individual peptide growth factors that could confer a
‘transformed’ phenotype on nonmalignant cells were identified (Sporn, 1999).
Repeated rounds of purification of extracts from virus transformed cells, which
initially was used to identify sarcoma growth factor (de Larco and Todaro, 1978),
identified two peptides responsible for growth of normal rat kidney epithelial
(NRK) cells on soft agar (Roberts et al., 1981; Anzano et al., 1983)). These
peptides were christened as transforming growth factor-alpha (TGFα) and
transforming growth factor-beta (TGFβ) (Roberts et al., 1983). TGFβ was purified
to homogeneity from human platelets, human placenta, and bovine kidney and
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characterized as a 25-kDa homodimer (Assoian et al., 1983; Frolik et al., 1983;
Roberts et al., 1983).
Structurally related peptides harboring a conserved set of cysteines
characterize the TGFβ family members (Kingsley, 1994; Massague, 1998; Shi
and Massague, 2003). Since the identification of TGFβ1 in 1980s, two other
distinct isoforms of TGFβ have been identified in mammals, TGFβ2 and TGFβ3.
Currently, this superfamily comprises 34 family members, inclusive of TGFβ,
Activins, Bone Morphogenetic Proteins (BMP), Vg1, Mullerian Inhibiting
Substance (MIS), Growth and Differentiation Factor (GDF) and Inhibin and is
highly conserved in organisms ranging from Caenorhabditis elegans, Drosophila
melanogaster, Xenopus laevis, and mammals (Massague, 1998).
Originally believed to stimulate cell proliferation and growth, TGFβ was
subsequently shown to have the potential to inhibit cell growth (Tucker et al.,
1984). Specifically, TGFβ1 is involved in immune suppression, angiogenesis,
apoptosis, cell growth, and epithelial to mesenchymal transitions (EMT) during
development and metastatic cancer progressions (Pepper, 1997; Bakin et al.,
2000; Akhurst and Derynck, 2001; Derynck et al., 2001; Dennler et al., 2002;
Moustakas et al., 2002; Roberts and Wakefield, 2003; Lamouille and Derynck,
2007; Massague, 2008; Xu et al., 2009).
1.2. TGFβ Signaling Cascade
Binding of TGFβ family ligands to the constitutively active TGFβ type II
serine/threonine kinase receptor (TβRII) results in the recruitment of type I
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receptor (TβRI) and the formation of a stable oligomeric receptor complex
(Yamashita et al., 1994). Formation of the complex results in the type II receptor
to phosphorylate the type I receptor at the C-terminal GS domain, a highly
conserved 30 amino acid sequence with a characteristic SGSGSG sequence
directly upstream of the kinase domain (Wrana et al., 1994a; Wrana et al.,
1994b; Wieser et al., 1995). This phosphorylation leads to a conformational
change resulting in type I receptor-kinase activation.
Recently, the structural basis for this two-step assembly process has been
revealed (Groppe et al., 2008). The extracellular domains of the TβRI and TβRII
fit snugly around the dimeric TGFβ as a six-piece puzzle. It was earlier shown
that TβRII binds the fingertip of the extended TGFβ3 ligand structure (Hart et al.,
2002), with a conserved N-terminal extension in TβRII remaining disordered. In
the active complex, seven residues of this N-terminal complex become ordered
resulting in active heterotetrameric complex formation. Also a five-residue finger
in TβRI was shown to hydrogen bond with an aspartate in TβRII, explaining the
lack of avidity of TβRI to free TGFβ ligand (Groppe et al., 2008; Massague,
2008). The activated TβRI interacts with and phosphorylates a number of
proteins,

thereby

activating

multiple

downstream

signaling

pathways.

Downstream of this the signal is broadly transduced in either a Smad-dependent
(canonical) or Smad-independent (non-canonical) signaling pathway.
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1.2.1. Canonical TGFβ Signaling Pathway
Smads are the central regulators: The Smads were identified as
intermediates of the decapentaplegic (dpp) signaling pathway in Drosophila
melanogaster (Raftery et al., 1995; Sekelsky et al., 1995). Loss of function
mutations in Mothers against dpp (mad) in Drosophila melanogaster resulted in
pupal lethality, gut defects, and other phenotypes similar to dpp mutant
phenotypes. Genetic screens in Caenorhabditis elegans identified sma-2, sma-3,
and sma-4 as genes that have mutant phenotypes similar to that observed for the
TGFβ-like receptor gene, daf-4 (Savage et al., 1996). From these data, it was
proposed that the mad and sma are homologous genes involved in TGFβ
signaling cascade. Later, murine and human homologues to the mad and sma
genes were identified and collectively called Smads (Baker and Harland, 1996;
Eppert et al., 1996; Derynck et al., 1996; Macias-Silva et al., 1996; Riggins et al.,
1996; Yingling et al., 1996; Zhang et al., 1996; Nakao et al., 1997).
To date eight mammalian Smad proteins have been characterized and are
divided into three functional sub-groups: the receptor-activated Smads (RSmads), common mediator Smad (Co-Smad), and the inhibitory Smads (ISmads). Human Smad2, Smad3 and Smad7 map to chromosome 18q21-22,
Smad3 and Smad6 map to chromosome 15q21-22, and Smad5, Smad1 and
Smad8 map to chromosome 15q31, 15q4, and 15q13 respectively (Eppert et al.,
1996; Moustakas et al., 2001). The R-Smads are directly phosphorylated by the
type I receptors on their carboxy terminal Ser-Ser-X-Ser (SSXS) motif and
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include Smad1, Smad2, Smad3, Smad5, and Smad8. Smad2 and Smad3 are
phosphorylated in response to the TGFβs and activin, whereas Smad1, Smad5,
and Smad8 are phosphorylated in response to BMP. The only mammalian CoSmad to be identified, thus far, is Smad4 and it mediates signals from both the
Thug/activin/TGFβ and BMP signaling pathways. Smad4 functions to assist in
the further transduction of the signaling pathways by oligomerizing with activated
R-Smad(s). The I-Smads, Smad6 and Smad7, are induced by BMP and/or
TGFβ/activin, respectively and act as negative feedback to inhibit activation of
the R-Smads by inducing degradation of the receptors or by competing with the
R-Smads for receptor binding (Massague, 1998).
The Smads are characterized by two conserved regions known as the
amino terminal (N-terminal) Mad homology domain-1 (MH1) and C-terminal Mad
homology domain-2 (MH2), which are joined by a short, poorly conserved linker
region. The MH1 domain is highly conserved among the R-Smads and the CoSmad, whereas the I-Smads lack a MH1 domain. The R-Smads and Smad4
have N-terminal nuclear localization signals (NLS) and Smad4 has a nuclear
export signal (NES) in the MH1 domain (Xiao et al., 2000; Kurisaki et al., 2001;
Xiao et al., 2003). The MH1 domain plays a role in R- and Co-Smad nuclear
import, cytoplasmic anchoring, DNA binding, and regulation of transcription. The
MH2 domain is conserved among all of the Smad proteins and regulates Smad
oligomerization, cytoplasmic anchoring, and transcription of target genes. The
MH1 and MH2 domains bind to a number of proteins including ubiquitination
adaptors and substrates, transcriptional co-activators and co-repressors, and a
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number of transcription factors (Moustakas et al., 2001). Furthermore, Smad3
has a transactivation domain in the linker region (Prokova et al., 2005). The
functional roles that are assigned to the linker region of the Smads are
ubiquitination and transcriptional activation.

Figure 1.1: Schematic representation of canonical and non-canonical TGFβ
signaling pathways.
Binding of TGFβ to its cognate receptor initiates the signaling pathway. In the canonical
pathway, activated type I receptors phosphorylates R-Smads, which subsequently form
a complex with the Co-Smad, Smad4. The resulting R-Smads/C0-Smad complex
translocates to the nucleus and interacts with distinct transcription factors to turn on or
off transcription of many TGFβ-responsive genes that regulate cell proliferation and
differentiation. Additionally, TGFβ activates different non-Smad pathways, including
PI3K, Ras, Par6, Jnk/p38/MAPK pathways, which cumulatively regulate TGFβ-mediated
functions.
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Receptor activation of Smad2 and Smad3: The role of adaptor
proteins in TGFβ Signaling: The Smad signaling cascade is initiated by Cterminal phosphorylation of Smad2 and/or Smad3 by activated TβR1 (MaciasSilva et al., 1996). However, in order for Smad2 and Smad3 to be
phosphorylated by TβRI, they must be recruited to the activated receptor
complex. A number of proteins have been identified to interact with Smad2
and/or Smad3 to regulate R-Smad phosphorylation. Smad anchor for receptor
activation (SARA) and hepatocytes growth factor-regulated tyrosine kinase
substrate (Hrs/Hgs) is FYVE domain containing proteins that present Smad2 to
TβRI (Tsukazaki et al., 1998; Miura et al., 2000). SARA is associated with the
plasma membrane and can interact with both non-phosphorylated R-Smads and
the TGFβ receptor complex (Tsukazaki et al., 1998). When the receptors become
activated, and the R-Smads are phosphorylated, the R-Smads dissociate from
SARA and the receptor complex, and bind to Smad4. SARA has a higher affinity
for monomeric Smads; therefore it is thought that SARA may also act to regulate
Smads by inhibiting aberrant R-Smad oligomerization (Qin et al., 1996). Hrs/Hgs
is localized to early endosomes and synergizes with SARA to present Smad2 to
the activated receptor complex (Tsukazaki et al., 1998; Burd and Emr, 1998;
Gaullier et al., 1998; Patki et al., 1998). It was earlier shown that Disabled-2
(Dab2) associates with TβRI and TβRII and functionally bridges the activated
receptors to Smad2 and Smad3 through its N-terminal phosphotyrosine-binding
(PTB)/-interacting (PID) domain (Hocevar et al., 2001). Additionally, TGFβ
receptor-associated protein-1 (TRAP-1) (Charng et al., 1998) and the adaptor
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protein embryonic liver fodrin (ELF) (Mishra et al., 2004) enable activation of RSmads by the activated TGFβ receptor complex. Endocytosis of the active TGFβ
receptor complex is another mechanism by which R-Smad activation is
regulated. There is sufficient evidence supporting and arguing against the
necessity for receptor endocytosis in R-Smad phosphorylation (Hayes et al.,
2002; Penheiter et al., 2002). The dependency on receptor endocytosis for RSmad activation may be cell-type dependent.
The Smad Pathway: The activated TβRI phosphorylates R-Smads at its
C-terminal SXSS motif. Phosphorylated R-Smads then form a complex with
Smad4. The resulting complex of R-Smads/Co-Smads moves to the nucleus and
functionally interacts with distinct transcription factors to turn on or off
transcription of many TGFβ-responsive genes that regulate cell proliferation and
differentiation (Massague, 1998). The L45 loop of activated type I receptor
interacts with the L3 loop of the Smad proteins (Massague, 1998). The
interaction plays an important role in determining the signaling specificity as the
structure of the L45 loop differ between receptors and dictates which Smads will
bind and be activated.
1.2.2. Non-canonical (Smad-independent) TGFβ signaling pathways
TGFβ signaling can activate the MAP kinases ERK, JNK, and p38 MAP
kinase (Hartsough et al., 1995; Atfi et al., 1997; Engel et al., 1999; Hocevar et al.,
1999; Bakin et al., 2002). Evidence for this activation came from studies with
Smad4-deficient cells and cells overexpressing dominant negative Smad4 (Engel
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et al., 1998). In these cells, JNK/MAPK activation was shown to be adequate to
elicit TGFβ regulated responses. Conversely, it was shown that TβRIs that were
incapable of activating downstream Smads could still activate p38. Recently it
was shown that activated TGFβ receptors directly induce polyubiquitination via a
lysine at position 63 (K63) of TRAF6, which subsequently is required for
activation of JNK and p38 (Yamashita et al., 2008). The consequences of MAPK
activation by TGFβ remain unclear, however evidence suggests ERK activation
is involved in TGFβ-mediated Ras signaling in epithelial cells. TβRs can also
directly activate RhoA to induce actin stress fiber formation in fibroblasts, albeit
evidences suggest a cooperative role of Smads (Bhowmick et al., 2001; Edlund
et al., 2002; Vardouli et al., 2005). TGFβ–induced EMT integrates Smad as well
as non-Smad signaling, and compulsorily requires signaling through PI3K/Protein
kinase B (Akt) pathway (14, 68). This happens as a follow-up of Par6 induced
ubiquitination and degradation of RhoA (Ozdamar et al., 2005).
The Smad proteins can also serve as the platform for signaling crosstalk
mechanisms. ERK has been shown to phosphorylate the linker region of Smad1,
Smad2, and Smad3 through the Ras pathway (Kretzschmar et al., 1997;
Kretzschmar et al., 1999). Phosphorylation of Smads by ERK prevents nuclear
translocation of the Smad complex to the nucleus, as a result of which cells
containing hyperactive Ras pathway become insensitive to TGFβ stimulation.
Contrasting reports have noted nuclear translocation of Smad complex in Ras
transformed cells and ERK-mediated Smad phosphorylation seems to increase
the half-life of Smad, stabilize complex formation with Smad4, enhancing the
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overall transcriptional activity of Smad2 (de Caestecker et al., 1998). Other
kinases, like protein kinase C (PKC) can directly phosphorylate Smad3 to
prevent its binding to DNA while NF-κβ and STAT signaling inhibit TGFβ
signaling by increasing induction of Smad7 expression (Ullola et al., 1999;
Yakymovych et al., 2001; Jenkins et al., 2005). Evidence also exists for the
cooperation between the TGFβ and Wnt pathway as well as cooperation
between p53 and Smads in modulating expression of TGFβ regulated genes
(Cordenonsi et al., 2003; Wilkinson et al., 2005; Jiang et al., 2008). Recently, it
has been shown that TGFβ acts in sync with Ras and mutant p53 to inhibit p63
and aid in metastatic progression of tumors (Adorno et al., 2009). The multi-step
crosstalk of Smad and non-Smad pathways affords a complex, yet meticulous
regulation of TGFβ signaling and greater understanding of these crosstalk
pathways in a cell type and context specific environment will elucidate the
physiological and pathological relevance of this tight regulation.
1.3. Regulation and Signal Attenuation of TGFβ Response
Attenuation of TGFβ signaling is mediated either by the I-Smads or
ubiquitination

and

proteosomal

degradation

of

Smad2/3.

The

I-Smads

antagonize TGFβ signaling by competitive inhibition of Smad2/3 binding to the
activated TβRI (Imamura et al., 1997; Hata et al., 1998; Nakao et al., 1997;
Ebisawa et al., 2001). Additionally, Smad7 dephosphorylates activated type I
receptor by initiating interactions with a complex containing GADD34 and protein
phosphatase 1 (Shi et al., 2004). Smad7 also contributes in signal attenuation by
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recruiting Smurf E3 ubiquitin ligase to type I receptor and initiating proteosomal
degradation, thereby preventing sustained TGFβ signaling after endocytosis of
the receptor complex into calveolar lipid rafts (Lin et al., 2000). Subsequent
internalization of the Type II receptors occurs as a result of β-arrestin2
recruitment of TGFβ signalosome at the receptor level. Smurf2 (Lin et al., 2000)
and Skp1-Cul1F-box protein (SCF) (Fukuchi et al., 2001), the Smad2 and Smad3
E3 ubiquitin ligase, respectively, mediates the degradation of Smad2 and
Smad3. Smad3 is also degraded through the carboxy terminus of Hsp70
interacting protein (CHIP) dependent degradation (McDonough and Patterson,
2003). Smad3 can interact directly with Hsp70 resulting in TGFβ independent
ubiquitination and degradation of Smad3 (Xin et al., 2005). This lends credence
to the homeostatic regulation of TGFβ-mediated signal amplification and
subsequent attenuation.
Co-repressors, like Ski and SnoN render an additional level of regulation
of TGFβ signaling. Within the nucleus, TGFβ stimulation potentiates Smad3 to
bind SnoN and promote its subsequent degradation by the anaphase promoting
complex (APC) or Smurf2 (Bonni et al., 2001; Stroschein et al., 1999). TGFβ
signaling transcriptionally induces SnoN, allowing for a negative feedback control
of TGFβ signaling (Stroschein et al., 2001). SnoN and Ski function to inhibit
TGFβ signaling by disrupting the Smad complex and by recruiting histone
deacetylases such as the N-CoR complex, to the chromatin (Wu et al., 2002).
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Finally, attenuation of the TGFβ signaling can also occur through
dephosphorylation of the Smad/Co-Smad complex. PPM1A was identified as the
phosphatase responsible for dephosphorylating the Smads and their subsequent
release from the nucleus (Lin et al., 2006). The dephosphorylated Smads were
shown to recycle back into the cytoplasm to await the next round of signaling (Lin
et al., 2006). However, whether degradation of proteins or the modulation of the
protein through post-translational modifications plays the dominant role in
abrogating TGFβ signaling remains to be elucidated. It is likely that ubiquitin
mediated proteosomal degradation and dephosphorylation events function
cooperatively and in a redundant fashion to ensure rapid kinetics and tight control
of TGFβ signal attenuation.
1.4. Paradoxical Role of TGFβ Signaling - The Yin and Yang of
Carcinogenesis
Extensive evidences exist for deregulated TGFβ signaling pathway as a
causative agent for tumor initiation and advanced stage disease progression.
TGFβ exerts antiproliferative effects and functions as a tumor suppressor during
early stages of tumorigenesis, whereas at later stages it functions as a tumor
promoter aiding in metastatic progression through an autocrine TGFβ loop (Bierie
and Moses, 2006). Transgenic mice expressing a dominant negative TβRII in
the epidermis and mammary glands show aggressive tumor formation and
metastatic progression (Amendt et al., 1998). Susceptibility of TGFβ-mediated
antiproliferative effects is absent in lung cancer (Yanagisawa et al., 2000), head
12

and neck squamous cell carcinoma (Garrigue-Antar et al., 1995), prostate cancer
(Park et al., 2000), gastric cancer (Myeroff et al., 1995; Kang et al., 1999), colon
cancer (Eppert et al., 1996; Markowitz et al., 2000), pancreatic cancer (Goggins
et al., 1998), and breast cancers (Lucke et al., 2001). Recently it has been shown
that the tumor suppressor Merlin and a trans-acting negative regulator of
signaling, Erbin fine regulates the context dependent response to TGFβ signaling
(Wilkes et al., 2009). It was shown that in fibroblasts, Merlin is phosphorylated
and subsequently inactivated by p21 activated kinase 2 (PAK2), inducing growth
and proliferation. PAK2 activity in epithelial cells promotes apoptosis. To prevent
antiproliferative effects in epithelial cells Merlin recruits Erbin and disrupts
activation and function of PAK2 (Wilkes et al., 2009).
1.4.1. TGFβ as a tumor suppressor: cytostatic and pro-apoptotic effects
TGFβ functions as a tumor suppressor by mediating its antiproliferative effects in
a large variety of cell types. During early stages of tumorigenesis, TGFβ inhibits
cell cycle promotion and evasion of TGFβ-mediated antiproliferative effects is a
prerequisite for advancement of tumor progression (Akhurst and Derynck, 2001;
Derynck

et

al.,

2001;

de

Caestecker

et

al.,

2000).

TGFβ-mediated

downregulation of c-Myc is a central event of antiproliferative regulatory effects
(Mulder and Brattain, 1988; Mulder et al., 1988; Zentella et al., 1992). c-Myc
functions as a transcriptional activator or inhibitor, depending on the target gene,
thereby promoting cell growth through the G1 phase of the cell cycle
(Alexandrow and Moses, 1995a; Facchini and Penn, 1998; Dang, 1999). Ectopic
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overexpression of c-Myc results in insensitivity to the growth inhibitory effects of
TGFβ (Alexandrow and Moses, 1995b). Defective repression of c-Myc and
subsequent resistance to TGFβ is reported in a number of breast cancer cell
lines. Repression of c-Myc by TGFβ has been shown to occur through the Smad
pathway (Yagi et al., 2002).
Additionally, TGFβ induces the cyclin-dependent kinase inhibitors (CKIs)
p15 and p21 (Alexandrow and Moses, 1995b; Datto et al., 1995; Reynisdottir and
Massague, 1997; Iavarone and Massague, 1997; Moustakas and Kardassis,
1998; Robson et al., 1999). TGFβ transcriptionally upregulates p15 expression in
a Smad-dependent fashion through inhibition of Cyclin D1/Cdk4 (Sandhu et al.,
1997). TGFβ-dependent induction of p21 and/or p27 also regulates Cdk activity
(Alexandrow and Moses, 1995b; Datto et al., 1995; Reynisdottir and Massague,
1997; Iavarone and Massague, 1997; Moustakas and Kardassis, 1998; Robson
et al., 1999). p21 directly interacts with and inhibits Cyclin D-Cdk4/6, Cyclin ECdk2, and Cyclin A-Cdk2 complexes, therefore arresting progression of the cell
cycle in the late G1 phase (Harper et al., 1993). TGFβ regulation of the p21
promoter involves Sp1 and the Smads (Moustakas and Kardassis, 1998). But
contrasting reports have shown that lymphocytes from p27 deficient mice remain
sensitive to the growth inhibitory effect of TGFβ; therefore, suggesting that p27
may not be actually necessary for TGFβ-induced cell cycle arrest (Nakayama et
al., 1996). Cell division cyclin 25A (Cdc25A) mRNA and cyclin activating kinase
(CAK) activity is downregulated by TGFβ (Reynisdottir and Massague, 1997;
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Nagahara et al., 1999; Bhowmick et al., 2003). Cdc25A is a Cdk tyrosine
phosphatase that functions to inactivate Cdks by dephosphorylating

Figure 1.2: Paradoxical effects of TGFβ signaling.
In normal epithelium TGFβ functions as a tumor suppressor through its antiproliferative
and pro-apoptotic effects. But with tumor progression, autocrine loops of TGFβ are
activated and in the tumor milieu resistance to the growth inhibitory effects of TGFβ is
acquired. Epithelial cells transdifferentiate to mesenchymal cells through a TGFβdependent phenomenon, called epithelial to mesenchymal transition (EMT), with
concomitant loss of adherens and tight junctions, loss of E-cadherin expression, and
increase in mesenchymal cell markers such as dab2, N-cadherin, and ILEI. EMT renders
mobility to the tumor cells, which is a critical pre-requisite for metastatic progression of
the tumor. Both Smad-dependent and Smad-independent pathways are involved in
TGFβ-mediated EMT.
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threonine/tyrosine residues that are necessary for full activation of the Cdks. In
contrast, CAK phosphorylates Cdks on a conserved threonine residue. Without
this phosphorylation, the Cdks cannot be fully active. The decrease in Cdc25A
expression, mediated by TGFβ, was observed in mammary gland epithelial cells
(Iavarone and Massague, 1997; Bhowmick et al., 2003). As a result of TGFβmediated downregulation of Cdc25A and inactivation of CAK, the Cdks are not
fully active and cell cycle progression stops during G1 phase.
Pro-apoptotic effects of TGFβ also contribute towards its cytostatic effects.
TGFβ-induced apoptotic response has been seen in prostate epithelium,
hepatocytes and hepatoma cell lines, B-lymphocytes and B-cell lines (SanchezCapelo, 2005). TRAIL and the AP-1/Smad pathway (Herzer et al., 2008), Daxx
and the JNK pathway (Perlman et al., 2001), DAPK and the Smad pathway (Jang
et al., 2002), GADD45b and the p38 pathway (Yoo et al., 2003), and ARTS, a
mitochondrial protein that aids in caspase activation (Gottfried et al., 2004) have
all been indicated to be involved in TGFβ-mediated apoptotic events. TGFβinduced expression of the pro-apoptotic protein, Bim, induces cell death in Blymphocytes (Wildey et al., 2003). It was also shown that stimulation of the prosurvival CD40 receptor inhibited TGFβ-mediated Bim expression and subsequent
apoptosis in WEHI1231 B-lymphocytes (Patil et al., 2000). Smad3-dependent
Bim induction has been shown in gastric epithelial cells undergoing TGFβinduced apoptosis (Ohgushi et al., 2005), and in AML12 hepatocytes (Ramesh et
al., 2009). Evidence suggests that Smad3 and Bim are critical mediators of
TGFβ-induced apoptosis (Ramesh et al., 2003).
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1.4.2. TGFβ as a promoter of metastatic progression: TGFβ-Mediated
Epithelial to Mesenchymal Transition (EMT)
Alternatively, phosphorylation of the polarity protein Par6 by the activated
receptor complex has also been shown to be involved in EMT. During metastatic
progression, TGFβ promotes epithelial to mesenchymal transition (EMT)
(Derynck et al., 2001; Moustakas et al., 2002; Zavadil and Bottinger, 2005),
which is accompanied by a concomitant loss of cell-cell and cell-matrix adhesion
and morphogenic changes from a polarized epithelial phenotype to an elongated
fibroblastoid or mesenchymal phenotype (Zavadil and Bottinger, 2005; Thiery
and Sleeman, 2006). TGFβ-induced EMT is also indispensable during embryonic
development for neural crest, heart, and craniofacial structures formation
(Trelstad et al., 1967; Massague, 2008). It is interesting to note that EMT during
development is largely spatially and temporally regulated, whereas the EMT seen
during advanced cancer progression may not reflect the order and timing of
events observed during development (Larue and Bellacosa, 2005). EMT has a
critical role in cancer cell motility, invasion and metastasis. In order for cancer
cells to invade surrounding tissues and metastasize to distant sites it is
necessary for the cells to dissociate and penetrate the basement membrane,
characteristics of developmental EMT.
Evidence suggests that non-Smad signaling pathways are primarily
involved in the induction of EMT by TGFβ. Signaling through integrin β1
(Bhowmick et al., 2001), p38MAPK (Bakin et al., 2002), phosphoinositide 317

kinase (PI3K) (Bakin et al., 2000; Gotzmann et al., 2002; Kattla et al., 2008), Ras
homologous (Rho) A (Bhowmick et al., 2001; Janda et al., 2002), Jagged/Notch
(Zavadil et al., 2004), nuclear factor κβ (NF-κβ) (Huber et al., 2004) have all been
shown to be required for TGFβ-induced EMT. TGFβ treatment of nontransformed murine NMuMG cells and mouse cortical tubule (MCT) cells resulted
in an induction of EMT (Xie et al., 2004; Prunier and Howe, 2005) and treatment
of the cells with the MEK inhibitor U0126 blocked TGFβ-mediated induction of
EMT (Xie et al., 2004).
Significance of Dab2 and ILEI in TGFβ
β-mediated EMT: Two established
in vitro models for studying TGFβ-induced EMT are normal murine mammary
gland epithelial (NMuMG) cells and mouse mammary epithelial cells, EpH4,
transformed with oncogenic Ras (EpRas) (Miettinen et al., 1994; Oft et al., 1996;
Thuault et al., 2006). Using these models, two candidate EMT genes were
defined, Disabled-2 (Dab2) (Prunier and Howe, 2005) and FAM3C or interleukin
like EMT inducer (ILEI) (Jechlinger et al., 2003; Waerner et al., 2006). Dab2 is a
putative tumor suppressor gene, but modulates late stages of tumor progression
by promoting EMT-dependent metastasis (Mok et al., 1994; Prunier and Howe,
2005). Dab2 protein is aberrantly low in many types of tumors, yet the molecular
basis for its loss is unknown (Bagadi et al., 2007). Dab2 is involved in
homeostatic balance of epithelial cell differentiation, a role confirmed by several
genetic studies demonstrating a function for Dab2 in endodermal cell formation,
organization, and differentiation (Sheng et al., 2000; Morris et al., 2002; Yang et
al., 2002). ILEI was initially identified as a candidate gene for autosomal
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recessive nonsyndromic hearing loss locus 17 (DFNB17) (Greinwald et al., 1998)
and was subsequently identified as a member of a recently discovered gene
family (FAM3A-D) (Zhu et al., 2002). In a translational-state microarray analysis
(also called “polysome profiling) in which differential sedimentation is used to
separate heavy, ribosome-enriched, rapidly translating mRNAs (polysomes) from
light, ribosome-poor, slowly translating mRNAs (monosome), ILEI was shown to
be translationally upregulated during EMT (Jechlinger et al., 2003; Waerner et
al., 2006).
It has been previously demonstrated that shRNA-mediated silencing of
Dab2 in NMuMG cells was sufficient to inhibit TGFβ-mediated EMT as analyzed
morphologically and by loss of upregulation of N-cadherin, a mesenchymal cell
marker (Prunier and Howe, 2005). More importantly, re-expression of human
Dab2 in Dab2 knock-down cells restored TGFβ-mediated EMT and N-cadherin
up-regulation (Prunier and Howe, 2005). Stable knockdown of ILEI has also been
shown to inhibit TGFβ-mediated EMT in EpRas cells (Waerner et al., 2006),
whereas ILEI expression can cause epithelial plasticity changes and tumor
formation in non-tumorigenic NMuMG cells and 3T3 fibroblasts (Waerner et al.,
2006). Cumulatively, it can be inferred that both Dab2 and ILEI are required, but
not sufficient alone (i.e., in a TGFβ-independent fashion) to induce EMT.
Activated Ras/Raf/Mitogen activated protein kinase (MAPK) pathway has
been implicated for TGFβ-mediated EMT in human, rat, or mouse epidermal,
pancreas, intestine, liver, prostate, and mammary epithelial cells (Oft et al., 1996;
Oft et al., 1998; Bhowmick et al., 2001; Gotzmann et al., 2002; Davies et al.,
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2005). In other models, TGFβ stimulates ERK, whose function is required for the
relocalization of adherens junctions and cell motility induced by TGFβ. In
addition, TGFβ activates both Snail and Slug, zinc-finger proteins that repress
transcription of E-cadherin in certain cell culture models of EMT (Zavadil et al.,
2001; Saika et al., 2004; Giannelli et al., 2005).
TGFβ signaling through TβRI and TβRII has also been implicated for
TGFβ-mediated EMT and Smad overexpression has been shown to cause
synergistic induction of EMT when combined with activated TGFβ receptors (Oft
et al., 2002). Ectopic expression of Smad2 or Smad3, along with Smad4, in
human and mouse non-transformed cell lines enhanced TGFβ-induced EMT,
whereas the expression of a dominant negative Smad2, Smad3, or Smad4
blocked TGFβ-mediated EMT (Valcourt et al., 2005). In vivo evidence for Smad3
involvement in EMT result from experiments in Smad3 knockout mice where loss
of Smad3 blocks injury-induced EMT in primary lens epithelial cells and fails to
induce EMT in primary tubular epithelial cells derived from Smad3-/- mouse
kidneys (Saika et al., 2004; Valcourt et al., 2005). More recently it was shown
that after deletion of Smad3 in mouse hepatocytes, TGFβ induced EMT only in
control hepatocytes but not in Smad3-/- hepatocytes (Ju et al., 2006), suggesting
involvement of Smad-dependent signaling in TGFβ-mediated EMT.
1.5. Translational Regulation
Protein synthesis is a multi-step, multi-factorial pathway in which
regulation can be exerted at many levels. Actively translating mRNAs usually
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consist of a 5’ m7gpppN cap, 5’-UTR, coding region, 3’-UTR and poly (A) tail.
The process of translation can be separated into three distinct stages: initiation,
elongation and termination (Wickens et al., 1996; van der Kelen et al., 2009).
During initiation, the 40S ribosomal subunit binds to the 5’-cap of an mRNA,
scans in the 5’ to 3’ direction until the first AUG is encountered, stalls to recruit
the 60S subunit, and forms the 80S ribosomal unit, which then proceeds with the
translation elongation step. Elongation begins after delivery of a cognate
aminoacyl-tRNA (aa-tRNA) by EF1A1 to the ribosomal A-site and translocation of
the aa-tRNA to the P-site by EF-2. The α subunit of EF-1 binds aa-tRNA in a
GTP-dependent manner, and this ternary complex then binds to the elongating
ribosome. Once the cognate aa-tRNA is bound to the A-site, hydrolysis of GTP
occurs, releasing EF1A1 from the ribosome. Termination occurs when the
translating ribosome encounters stop codons in the A site. The stop codon is
recognized by eukaryotic release factor 1 (eRF1), which binds to the A site and
catalyzes the hydrolysis of the ester bond linking the polypeptide chain to the P
site tRNA thus allowing the peptide chain to be released from the ribosome.
Translational control is an essential cellular process that governs the
development and homeostasis of cells and tissues (Ruvinsky and Meyuhas,
2006) and defines a paradigm of control for different signaling pathways (Hay
and Sonenberg, 2004; Lamouille and Derynck, 2007). Deregulation of the
translation machinery has been implicated as causative agents responsible for
alterations of cell cycle progression and cell growth during changes in nutrient
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status, stress and carcinogenesis (Mazumder and Fox, 1999; Standart and
Jackson, 1994; Ruggero and Pandolfi, 2003). Given the quick pace and overall
energetically efficient nature, translational regulation is evolving as an important
regulatory step of gene expression (Mazumder and Fox, 1999; Sampath et al.,
2004).
Translational regulation can either be global through effects on eukaryotic
translation initiation factor 2 α-subunit (eIF2α) (Clemens, 1996); or, transcript
selective, mediated by putative cis regulatory elements in the 5’ and 3’ UTRs of
mRNAs and trans factor(s) binding to the regulatory cis elements (Jackson,
1993; Standart and Jackson, 1994; Decker and Parker, 1995; Hentze, 1995;
Mazumder and Fox, 1999; Sampath et al., 2004). The ‘human genome project’
reported the mean lengths of 5’-untranslated regions (UTRs) and 3’-UTRs of
human mRNAs as 300nt and 770nt, respectively, compared to the mean coding
length of 1340nt (International Human Genome Sequencing Consortium, 2001;
Reimann et al., 2002), generating renewed interest in the 3’-UTRs of mRNAs to
map translational regulatory activities. 3’-UTR’s have been shown to be involved
in multiple translational regulatory mechanisms, including mRNA translation
initiation (Black et al., 1997; Izquierdo et al., 1997; Ostareck et al., 1997), mRNA
stability (Sachs, 1997), mRNA localization (Zoladek et al., 1995), and in control of
poly(A) chain length (Sachs and Deardorff, 1992).
Transcript-selective translational control is achieved by the binding of a
RNA binding protein (trans factor) to putative, regulatory cis elements in the
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untranslated regions of target mRNAs. Most known examples of translational
inhibition attribute a negative regulatory function to the trans factor (Mbella et al.,
2000). The mechanism by which a protein bound to the 3’-UTR inhibits ribosome
assembly at the 5’ end is not yet known. The current hypothesis is the existence
of a closed-loop structure during mRNA translation and circular mRNA
complexes have been visualized by atomic force microscopy (Wells et al., 1998).
Trans factors that interact with putative cis elements, might affect this closed-loop
model and thus affect translation efficiency (Bormann et al., 2000).
The trans factors are RNA binding proteins harboring defined RNA binding
domains.

Among

the

various

RNA

binding

proteins,

heterogeneous

ribonucleoprotein E1 (hnRNP E1) (also called poly(rC)-binding protein or α−CP1)
has been implicated in the translational regulation and mRNA stability of many
transcripts, including gastrin (Lee et al., 2007), A2 response element (Kosturko et
al., 2006), collagen I, III (Thiele et al., 2004), renin (Morris et al., 2004), folate
receptors (Antony et al., 2004), and 15-lipoxygenase (Ostareck et al., 1997).
hnRNP E1 is a ubiquitously expressed protein (Meng et al., 2007) and contains
three copies of the RNA binding domain, KH (K-homologous) (Gibson et al.,
1993; Siomi et al., 1993). hnRNP E1 preferentially binds to poly(C) region of
mRNA (Aasheim et al., 1994), but has also been shown to bind poly(U) stretch
(Leffers, 1995), albeit with less affinity. hnRNP E1 exists in both phosphorylated
and unphosphorylated forms (Leffers, 1995; Meng et al., 2007) and it has been
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predicted that the phosphorylated form has comparatively less RNA binding
capacity (Leffers, 1995).
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CHAPTER II
TGFβ-MEDIATED TRANSCRIPT-SELECTIVE TRANSLATIONAL ACTIVATION
OF DAB2 AND ILEI IS DIRECTED BY A NOVEL STRUCTURAL ELEMENT IN
THE 3’UTR OF THE MESSENGER RNAS AND HETEROGENEOUS NUCLEAR
RIBONUCLEOPROTEIN E1 (hnRNP E1)

2.1. Abstract
TGFβ induces epithelial-mesenchymal transdifferentiation (EMT) accompanied
by cellular differentiation and migration. Despite extensive transcriptomic
profiling, identification of TGFβ-inducible, EMT-specific genes has met with
limited success. Here, we identify a post-transcriptional pathway by which TGFβ
modulates expression of EMT-specific proteins. We show that heterogeneous
nuclear ribonucleoprotein E1 (hnRNP E1) binds a structural, 33 nucleotides (nt)
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TGF beta-activated translation (BAT) element in the 3’-UTR of disabled-2 (Dab2)
and interleukin-like EMT inducer (ILEI) transcripts, and repress their translation.
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2.2. Introduction
Epithelial-mesenchymal transition (EMT), in which cells undergo a switch from a
polarized, epithelial phenotype to a highly motile fibroblastic or mesenchymal
phenotype is fundamental during embryonic development and can be reactivated
in a variety of diseases including fibrosis and cancer (Derynck et al., 2001;
Zavadil and Bottinger, 2005; Bierie and Moses, 2006; Thiery and Sleeman, 2006;
Massague, 2008). TGFβ is one of the growth factors implicated in EMT
(Massague, 2008). Using normal murine mammary gland epithelial (NMuMG)
cells (Miettinen et al., 1994; Thuault et al., 2006) and mouse mammary epithelial
cells, EpH4, transformed with oncogenic Ras (EpRas) (Oft et al., 1996) as in vitro
models for TGFβ-induced EMT two candidate EMT genes were defined,
Disabled-2 (Dab2) (Prunier and Howe, 2005) and FAM3C or interleukin like EMT
inducer (ILEI) (Waerner et al., 2006). Dab2 is a putative tumor suppressor gene,
but modulates late stages of tumor progression by promoting EMT-dependent
metastasis (Prunier and Howe, 2005). ILEI was initially identified as a candidate
gene for autosomal recessive nonsyndromic hearing loss locus 17 (DFNB17)
(Greinwald et al., 1998) and was subsequently shown to belong to the FAM3A-D
gene family (Zhu et al., 2002). ILEI was shown to be translationally upregulated
during EMT in EpRas cells (Waerner et al., 2006). Short hairpin RNA (shRNA)mediated silencing of Dab2 in NMuMG cells inhibits TGFβ-mediated EMT and reexpression of human Dab2 in Dab2 knock-down cells restores TGFβ-mediated
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EMT (Prunier and Howe, 2005). Stable knockdown of ILEI inhibits TGFβmediated EMT in EpRas cells, whereas ILEI expression induces epithelial
plasticity changes and tumor formation in non-tumorigenic NMuMG cells and 3T3
fibroblasts (Waerner et al., 2006). These cumulatively suggest that both Dab2
and ILEI are required, but not sufficient (i.e., in a TGFβ-independent fashion) to
induce EMT. However, the molecular mechanism by which expression of Dab2
and ILEI is regulated by TGFβ remains elusive.
Here, we show that post-transcriptional regulation of gene expression
plays an important role in TGFβ-mediated EMT. We have identified a novel, 33nt
structural element in the 3’-UTRs of Dab2 and ILEI that inhibit translation of the
messages, an inhibition that is relieved following TGFβ treatment of cells. The
33nt element is sufficient to mediate translational inhibition in vitro and in vivo.
Using the 33nt 3’-UTR element, we have affinity purified the mRNP complex and
have identified hnRNP E1 as a critical component of this complex. Coordinate,
functional regulation of EMT inducer genes by the common 3’-UTR 33nt element
may represent a system similar to a prokaryotic regulon (Keene and Tenenbaum,
2002; Ray and Fox, 2007).
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2.3. Materials and Methods
2.3.1. Reagents.
Rabbit reticulocyte lysate, methionine free amino acids, RNasin, Dual
Luciferase Reporter Assay system and RiboMAX Large Scale RNA Production
kit were purchased from Promega. MAXIscript, and mMESSAGE mMACHINE T7
Ultra kits were purchased from Ambion. Primers and oligos were purchased from
Integrated DNA technologies. Translation grade [35S]-methionine and [α-32P]UTP were purchased from Perkin Elmer Life Sciences. Mouse α-hnRNP E1 was
from Novus Biologicals, rabbit α-hnRNP E1 was from Lifespan Biosciences. αFAM3C antibody was obtained from Abcam; α-Hsp90 (H-114) and α-hnRNP K
(F45P9C7) antibodies and normal mouse and rabbit IgG were purchased from
Santa Cruz Biotechnology.
2.3.2. Cell culture.
TGFβ2 was a generous gift from Genzyme Inc. and was used at a final
concentration of 5 ng/ml. NMuMG cells were cultured as described previously
(Prunier and Howe, 2005). EpRas were maintained in Dulbecco’s modified
Eagle’s

medium

supplemented

with

10%

fetal

bovine

serum

and

antibiotics/antimycotics.
2.3.3. Plasmids construction and protein expression.
The conserved 575 nt. (downstream of the stop codon) in Dab2 3’-UTR
was amplified using primers (mDab2-3’-UTR-F1/mDab2-3’-UTR-R2) from mouse
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cDNA

and

cloned

into

pcDNA3

downstream

of

the

T7

promoter

(pcDNA3/Dab2575-UTR) via Pac1 and Not1 sites (refer to Table I for primer
sequences). For synthesis of the deletion and internal fragments, 5’-and 3’primers were designed to generate Dab2 3’-UTR fragments having upstream T7
promoter sequence. For sequences less than 30 nucleotides, oligonucleotides
complementary to the desired sequence were synthesized with complementary
T7 promoter sequence at the 3’-end, and were annealed to an oligonucleotide
containing the T7 promoter sequence in STE buffer (0.1 M NaCl, 10 mM Tris-HCl
[pH, 8.0], 1 mM EDTA). The oligonucleotides were PAGE purified before
annealing.
For construction of the Luc-Dab2/BAT, Luc-Dab2/BAT-M mutant and LucILEI/BAT, luciferase cDNA derived from pGL3-b vector was cloned into pcDNA3.
A linker region containing 5’-EcoR1-Pac1-EcoRV-Nco-1-Xho-1-Xba-1 was
inserted into the vector downstream of the luciferase gene (pCMV-LL). Synthetic
Dab2/BAT, Dab2/BAT-M and ILEI/BAT were generated with 5’-EcoR1 and 3’Xba-1 sites (pCMVLuc-Dab2/BAT, pCMVLuc-Dab2/BAT-M, pCMVLuc-ILEI/BAT).
The GST-hnRNP E1 construct was a kind gift from Dr. R. Kumar and has
been previously described (Meng et al., 2007). The GST clones were maintained
in E. coli BL21 (DE3)pLysS for expression. For expression, the protocol as
described before was followed (Meng et al., 2007).
2.3.4. Isolation of RNA, Northern Blot and RT-PCR.
Isolation of total RNA, northern blot and RT-PCR was done as described
previously (Wildey et al., 2003). Refer to Table I for primer sequence. The Dab2
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probe specific for the p96 isoform was generated by PCR using primers listed in
Table I.
2.3.5.

Preparation

of

cell

lysates,

immunoblot

analysis,

immunoprecipitation and immunodepletion.
For immunoprecipitation and immunoblot analysis, cells were lysed in
buffer D and immunoprecipitation carried out as previously described (Hocevar et
al., 1999). For immunodepletion, indicated amounts of control cytosolic extracts
from NMuMG cells were incubated with mouse α-hnRNP E1 antibody or mouse
IgG coupled to Protein G agarose beads in cytosolic extraction buffer. The beads
were pelleted and the supernatant was subjected to another round of
immunodepletion. The supernatants were immunoblotted with rabbit α-hnRNP
E1 antibody to confirm immunodepletion.
2.3.6. Preparation of cytosolic extract (S100 Fraction).
S100 fractions were prepared from control and TGF-treated NMuMG
cells as previously described (Mazumder and Fox, 1999) with minor
modifications. Briefly, the buffer used for cytosolic extraction contained 20 mM
Hepes (pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM
DTT and protease inhibitor cocktail (Roche) (Hampton et al., 1998).
2.3.7. Polysome analysis.
Polysome analysis was performed as previously described (Ray and Fox,
2007) with minor modifications. For polysomes release experiments polysome
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lysis buffer containing 10 mM EDTA was used as described previously (Ray and
Fox, 2007).
2.3.8. Metabolic labeling.
NMuMG cells were treated with TGFβ for up to 24 hr. During the last 3 hr
of treatment cells were maintained in methionine-free medium containing [35S]methionine (100 µCi/ml). To detect de novo synthesis of Dab2 protein, cell
lysates were made and subjected to immunoprecipitation with mouse α-Dab2
antibody and mouse IgG as described previously (Hocevar et al., 1999). The
immunoprecipitated complexes were resolved by 10% SDS-PAGE, fixed and
visualized by autoradiography.
2.3.9. In vitro translation of Dab2 mRNA by a cell free translation-competent
system.
In vitro translation was done as described previously (Mazumder and Fox,
1999).

An

aliquot

of

the

translated

products

were

subjected

to

immunoprecipitation using mouse anti Dab2 antibody and normal mouse IgG as
described previously (Hocevar et al., 1999). Immunoprecipitated protein was
resolved by 10% SDS-PAGE, fixed and visualized by autoradiography.
2.3.10. In vitro transcription and UV crosslinking assay.
Radiolabeled, synthetic transcripts of the 575 nt of Dab2 3’-UTR was
prepared by in vitro transcription of linearized pcDNA3/Dab2575-UTR, using T7
RNA polymerase using MaxiScript kit in the presence of

[32P]-UTP. The

transcripts were purified by passing through MicroBiospin columns (BioRad) and
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were resolved on 15% Urea-acrylamide gel. The synthetic probes were gel
eluted and quantitated using a scintillation counter. Synthetic probes for the
various fragments were similarly made using the T7 RNA polymerase system as
each of these fragments had a 5’-T7 promoter. UV crosslinking was done as
described previously (Legagneux et al., 1992). Excess cold WT or mutant Dab2
33nt and 33nt ILEI RNAs were used in decoy experiments.
2.3.11. In vitro luciferase assay.
In vitro luciferase assay was performed as previously described
(Mazumder and Fox, 1999). Excess (2-10 folds) Dab2 3’-UTR BAT cRNA was
used in decoy experiments.
2.3.12. In vivo luciferase assay.
NMuMG cells were co-transfected with 10 µg of pCMVLuc-Dab2/BAT,
pCMVLuc-Dab2/BAT-M, pCMV-LL along with 1 µg of pCMVRenilla (Promega) using
Lipofectamine reagent. Cells were allowed to recover for 24 hr and then treated
with TGFβ for up to 24 hr. Dual (firefly and Renilla) luciferase activities were
determined by the Dual Luciferase Reporter assay system. The Renilla luciferase
activity was used as an internal control for uniform transfection efficiency. The
firefly luciferase activity was normalized to renilla luciferase activity and
expressed as percent control.
2.3.13. PatSearch and MFold analysis.
The PatSearch syntax was used to define a query pattern based on the
structure and sequence information of the Dab2 33nt element (Grillo et al., 2003;
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Ray and Fox, 2007). The query pattern was used to search a nonredundant 3’UTR sequence database. MFold algorithm was used to predict RNA secondary
structures (Zuker, 2003).
2.3.14. Size-Exclusion chromatography.
Size exclusion chromatography was performed as described previously
(Sampath et al., 2004).
2.3.15. RNA pull-down and isolation of mRNP complex binding to BAT
element.
WT and mutant Dab2 BAT synthetic RNA (cRNA) was bound to cyanogen
bromide-activated sepharose beads. RiboMax kit was used to generate
milligrams quantity of synthetic 33nt RNA from the template DNA. For RNA pull
down experiments, different amount (0.2-1 mg) of cytosolic extracts prepared
from control and TGFβ treated NMuMG cells were pre-cleared using the
Dab2/BAT-M cRNA-beads and then incubated at 4 0C for 2 hr with the Dab2/BAT
cRNA beads. Following the incubation period the beads are washed with 0.3 M
sodium chloride and resolved by 10% SDS-PAGE. In some experiments the
mRNP complex is eluted from the beads by washing with 1 M sodium chloride
and then concentrated and desalted using YM-3 desalting columns (Millipore).
Size-exclusion fractions that were showing translational repression activity were
subjected to RNA pull down as described above. The indicated bands were
trypsinized

and

peptide

sequences

determined

by

capillary

liquid

chromatography-electrospray mass spectrometry. The data obtained were
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analyzed using TurboSequest software to query the NCBI nonredundant protein
database. Matching spectra was confirmed by manual interpretation using
Mascot and FASTA software.
2.3.16. Determination of in vivo interaction between hnRNP E1 and Dab2 or
ILEI mRNA
In vivo interaction was investigated as described previously (Ray and Fox,
2007).
2.3.17. Statistical analysis
Data are presented as mean ± s.d., n=3 samples per group. The renilla
luciferase activity was used as an internal control for uniform transfection
efficiency. The firefly luciferase activity was normalized to renilla luciferase
activity and expressed as percent control.
Table I. Primers and oligonucleotide sequences for various constructs.

Name

Primer/oligonucleotide sequence (5’→3’)

mDab2-3’-UTR-F1

ATTTAATTAAGTTGTATGATGACTATCCAGATGAGCAA

mDab2-3’-UTR-R2

AAGCGGCCGCAGTTAGCTGAGAAACGACCATCTCAAAATGGT

hnRNP E1 shRNA

GATCATGTAAGAGTGGAATGTTATTCAAGAGATTGCCCAATAGCCTTTCACTTTTTTGGAAA

3’-UTR Top
hnRNP E1 shRNA

AGCTTTTCCAAAAAAGTGAAAGGCTATTGGGCAATCTCTTGAATAACATTCCACTCTTACAT

3’-UTR Bottom
Primer for hnRNP

GATCCGCGAGGAGGCCGGCGCGCGG

E1 S43A Mutation
mActin-Exon4-F1

AGCTGTGCTATGTTGCTCTAGACTT

mActin-Exon5-R1

CACTTCATGATGGAATTGAATGTAG

mDab2-Exon9-F1

AAGCAGGACTTGGAAAGTTCTGT

mDab2-R2

CATTGCCTTTGAAGAGATCCAGAA
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2.4. Results
2.4.1. Lack of correlation between Dab2 mRNA and protein expression
levels in NMuMG and EpRas cells
The temporal relationship between Dab2 mRNA and protein expression
levels in TGFβ-treated NMuMG and EpRas cells was investigated. Dab2 mRNA
levels, as measured by Northern blot and semi-quantitative RT-PCR, were
steady and only slightly induced by TGFβ in both cell lines examined (Fig. 2.1A,
B). Dab2 protein expression, measured by immunoblot analysis (Fig. 2.2A, B),
revealed that control cells, despite having abundant Dab2 mRNA, have low
levels of Dab2 protein. Similarly, in cells treated with TGFβ for 3 hr, Dab2 protein
levels are low despite abundant mRNA levels. It is only after a 3 hr TGFβ
treatment that Dab2 protein levels begin to increase with maximal induction
observed at ~12 hr post-TGFβ stimulation. To confirm the low rate of synthesis of
Dab2 in control cells and those treated with TGFβ for short times, de novo Dab2
synthesis was measured by pulse labeling with [35S]-methionine. Cells were
treated with TGFβ for the times indicated and labeled for the last 3 hr of the
incubation period, followed by immunoprecipitation of Dab2 (Fig. 2.3). As shown,
little de novo synthesis occurred in control or 3 hr TGFβ-treated cells but Dab2
synthesis increased significantly between 3-6 hr of TGFβ stimulation and peaked
at ~12 hr post-TGFβ treatment.
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2.4.2. TGFβ translationally upregulates Dab2 expression
The absence of Dab2 protein expression in control cells was either due to
the lack of translatability of Dab2 mRNA or due to attenuation in Dab2
translation. To test transcript integrity, total RNA was isolated from NMuMG cells
treated with TGFβ and translated in vitro in a cell-free rabbit reticulocyte lysate
system in the presence of [35S]-methionine and translated products were
immunoprecipitated (IP) with α-Dab2 antibody. The in vitro translation efficiencies
of RNA isolated from NMuMG cells treated with TGFβ for different times were
identical (Fig. 2.4). These results indicate that the low levels of Dab2 protein
expression in control cells, and early following TGFβ treatment, are not due to
defective Dab2 mRNA, but perhaps due to an inhibition of Dab2 translation.
Transcript-specific translational silencing has been shown to involve
translocation of regulated transcripts between non-translating non-polysomal
pools containing cytoplasmic messenger ribonucleoprotein particles and
translationally active polysomal complex of translating mRNA with polyribosome
complexes (Aziz and Munro, 1987; Rouault et al., 1988; Mazumder and Fox,
1999). We examined whether TGFβ stimulation of NMuMG cells resulted in a
translocation of Dab2 mRNA from the non-translating non-polysomal pool to the
actively translating polysomal pool. Cell homogenates from control and 24 hr
TGFβ-treated NMuMG cells were separated into non-polysome and polysome
fractions by successive centrifugation through a 10-50% sucrose gradient and
fractionation by a UV fractionater with the lighter mRNP fraction eluting first and
the heavier polysomal fractions eluting last (Figure 2.5A, B; elution profiles). RNA
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was isolated from the fractions and subjected to RT-PCR analyses. In control
cells, where Dab2 protein is not expressed, Dab2 mRNA was absent from the
polysomal fractions (Fig. 2.5A). However, after a 24 hr TGFβ treatment, when
Dab2 protein expression is high, abundant Dab2 mRNA translocated to the
actively translating polysomes (Fig. 2.5B). RT-PCR with β-actin specific primers
showed continuous association of the mRNA with the polysomes irrespective of
TGFβ treatment (Fig. 2.5A, B). This indicates that the translational repression of
Dab2 mRNA observed in control cells is a transcript specific effect and not due to
a global inhibition of translation. Control experiments demonstrated that
treatment of cell homogenates with EDTA (10 mM) prior to fractionation
completely disrupted polysomal complex formation and resulted in the
translocation or release of the Dab2 mRNA, isolated from TGFβ-treated cells,
into the mRNP fractions (Fig. 2.6A, B, C). The polysome release experiment
validates the authenticity of the polysome analyses and rules out the observed
polysome association of Dab2 mRNA to non-specific interaction or heavy
molecular weight aggregates. Taken together, these data suggest that Dab2 is
translationally regulated in a TGFβ-dependent fashion.
2.4.3. Identification of a novel structural element in the 3’-UTR of Dab2 that
mediates translational regulation
We postulated that the conserved first 575 nt of Dab2 3’-UTR harbors a
cis regulatory element which regulates its expression. UV-crosslinking analysis
using this region as a probe revealed two proteins, which showed TGFβdependent loss of binding (Fig. 2.7). Fine mapping subsequently defined a 33-nt
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region as the cis element (Fig. 2.8A, B). We named this region ‘BAT’ for TGFβeta
activated translational element and this region carries a stem loop structure with
an asymmetric bulge. A U10A mutant was predicted to destroy this secondary
structure using ‘Mfold’ analysis (Fig. 2.8B) (Zuker, 2003). A ‘PatSearch’ algorithm
driven search of a non-redundant 3’-UTR database for similar structures
reconfirmed the Dab2 3’-UTR to harbor the BAT element (UTRdb ID:
3MMU027375), and additionally identified the 3’-UTR of ILEI (UTRdb ID:
3MMU039724) (Fig. 2.8B) (Grillo et al., 2003). Examination of the temporal
relationship between ILEI mRNA and protein expression levels showed a pattern
similar to Dab2 (Fig. 2.1B, 2.2B, 2.9A, B) and polysome profiling reaffirmed that
TGFβ translationally upregulates ILEI (Fig. 2.10). UV-crosslinking analysis and
decoy experiments using Dab2/BAT, its U10A mutant and ILEI/BAT showed that
the binding of the 50 and 40 kDa proteins were TGFβ-dependent (Fig. 2.11A)
and confirmed the specificity of the element (Fig. 2.11B).
2.4.4. The 33nt element confers translational silencing activity to a
heterologous transcript in vitro and in vivo
Control cytosolic extracts inhibited the translation of a chimeric luciferase
construct carrying wild-type BAT (Luc-Dab2/BAT) (Fig. 2.12A) but not that of the
construct carrying the U10A mutant (Luc-Dab2/BAT-M) in a dose-dependent
fashion, suggesting that proteins in these extracts bind the identified BAT
element and functionally repress translation (Fig. 2.12B). In vitro translation
repression of Luc-Dab2/BAT and Luc-ILEI/BAT was relieved after 3 hr of TGFβ
stimulation, (Fig. 2.13A). Decoy experiments further confirmed the BAT-specific
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translational repression of the chimeric luciferase cRNA by control cytosolic
extracts (Fig. 2.13B). Similarly, in vivo translation was found to be repressed in
control cells using the WT BAT chimera (Luc-BAT), but not the mutant chimera
(Luc-BAT-M), or the luciferase construct with no 3’-UTR (Luc-alone) (Fig. 2.14).
TGFβ relieved translation repression as early as 3 hr and by greater than 80% at
24 hr. These results established BAT as a novel, structural element sufficient to
mediate translational inhibition in vitro and in vivo.
2.4.5. Identification of hnRNP E1 as a protein binding to the Dab2 33nt
structural element
Size-exclusion chromatography of control extracts was used to isolate the
BAT binding mRNP complex responsible for translational inhibition. Fractions
#36-38 showed maximum translation silencing activity (Fig. 2.15A, B). The
fractions with maximum translation silencing activity were affinity purified by
precipitation with Dab2/BAT cRNA and visualized by silver staining (Fig. 2.16).
The lower

band

(Fig.

2.16,

arrowhead),

present

in

both

the

active

chromatographic fractions and control cytosolic extracts, was identified as
heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) through mass
spectrometric analysis. Immunoblot analysis confirmed the presence of hnRNP
E1 in the fractions with maximal translation silencing activity (Fig. 2.17A). TGFβ
induced the loss of binding of hnRNP E1 to both Dab2 and ILEI BAT element
after 3 hr of treatment (Fig. 2.17B), and the kinetics of hnRNP E1 release from
the BAT element correlated with the kinetics of de-repression of translational
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silencing in vitro (Fig. 2.13A) and Dab2 and ILEI protein induction by TGFβ (Fig.
2.2A, 2.9B).
hnRNP E1, together with heterogeneous nuclear ribonucleoprotein K
(hnRNP K), bind to poly r(C) regions, called differentiation control elements
(DICE) in 3’-UTR of 15-lipoxygenase and L2 mRNAs and mediate their
translational regulation (Ostareck et al., 1997). However, in pull down
experiments, despite both hnRNP E1 and hnRNP K being present in inputs, only
hnRNP E1 from control extracts bound the WT BAT cRNA, whereas hnRNP E1
in extracts from TGFβ-treated cells did not bind. The BAT-M did not pull down
either hnRNP E1 or hnRNP K, whereas a DICE cRNA pulled down both proteins
in a TGFβ-independent fashion (Fig. 2.17C). Immunodepletion of hnRNP E1 from
control cytosolic extracts caused loss of translational silencing activity as
assayed by in vitro translation of Luc-Dab2/BAT (Fig. 2.18A, B).
2.4.6. hnRNP E1 interacts with the 33nt element in vitro and in vivo
In vitro binding assays showed that GST-hnRNP E1 could be precipitated
in a dose-dependent manner by both Dab2 and ILEI BAT elements, but not by
the mutant (Fig. 2.19). In vivo interaction studies revealed that although Dab2
and ILEI mRNAs were steadily expressed, hnRNP E1 interacted with them only
in control cells (Fig. 2.20A, B, C). Hence, hnRNP E1 is a functional component of
the mRNP complex, binding to the BAT element in a TGFβ-dependent manner,
which correlates with the kinetics of translational activation of ILEI and Dab2.
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Figure 2.1: Dab2 and ILEI transcription is not significantly induced in NMuMG and
EpRas cells post TGFβ treatment.
(A) Northern blot analysis examining Dab2 expression levels in NMuMG cells treated
with TGFβ for the durations indicated. The lower panel shows a quantification of band
intensities analyzed by NIH Image J software. The Dab2 band intensity was normalized
to that of cyclophilin (1B15), then normalized to the t=0 unstimulated value.
(B) Semi-quantitative RT-PCR examining Dab2, ILEI, and β-actin expression levels in
EpRas cells treated with TGFβ for the durations indicated.
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A

Figure 2.2: Dab2 and ILEI protein expression levels are significantly induced post
TGFβ treatment in NMuMG and EpRas cells.
(A) Immunoblot analyses examining Dab2 protein levels in NMuMG cells treated with
TGFβ for the indicated durations. The lower panel shows a quantification of band
intensities analyzed by NIH Image J software. Dab2 band intensity was normalized to
Hsp90, then normalized to the t=0 unstimulated value.
(B) Immunoblot analyses examining Dab2 and ILEI protein levels in EpRas cells treated
with TGFβ for the indicated durations.
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Figure 2.3: TGFβ induces the de novo
synthesis of Dab2.
The de novo rate of Dab2 synthesis postTGFβ stimulation was measured by
metabolic labeling. NMuMG cells were
treated with TGFβ (5 ng/ml) for the times
indicated and metabolically labeled with
[35S]-methionine
in
methionine-free
medium for the last 3 hr of incubation.
WCLs were immunoprecipitated (IP) with
α-Dab2 antibody, resolved by SDSPAGE and detected by autoradiography.

Figure 2.4: Dab2 mRNA is stable even
under control conditions.
Dab2 mRNA stability analysis by in vitro
translation (IVT) of total RNA isolated from
NMuMG cells treated with TGFβ for the
times
indicated
followed
by
immunoprecipitation (IP) with α-Dab2
antibody and mouse IgG.
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Figure 2.5: TGFβ translationally upregulates Dab2 expression.
(A) & (B) Polysome profiling in unstimulated and TGFβ treated NMuMG cells.
Translocation of Dab2 mRNA from the non-polysomal to polysomal pool was analyzed
by semi-quantitative RT-PCR of RNA isolated from each fraction following polysome
profiling.
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Figure 2.6: Polysome release experiment confirmed authentic polysome isolation.
(A) NMuMG cells were stimulated with TGFβ for 0 and 24 hr and treated with
cycloheximide (100 µg/ml) for the last 15 min of the incubation time. Cells were
homogenized in either buffer containing cycloheximide (100 µg/ml) or EDTA (10 nM) and
centrifuged at low speed. The post-mitochondrial supernatants were layered on a 1015% (w/v) sucrose gradient and centrifuged and the non-polysomal and polysomal
fractions were isolated through a fractionater. The panels show representatives UV
absorbance peaks during polysome fractionation with and without EDTA.
(B) & (C) RNA associated with each fraction was isolated and equal amounts of RNA
were subjected to RT-PCR with primers specific for Dab2 (B), and β-actin (C).
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Figure 2.7: UV crosslinking analysis reveals TGFβ-dependent loss of binding of
proteins to 3’-UTR of Dab2 mRNA.
UV crosslinking (X-link) analysis to characterize regulatory element(s) in the 3’-UTR of
Dab2 mRNA using [α-32P]-labeled Dab2 3’-UTR 575-nt probe (10 fmol) and S100
cytosolic extract from NMuMG cells treated with TGFβ for the times indicated.
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Figure 2.8: Translational silencing is mediated by a novel structural element.
(A) Schematic representation of deletion mapping used to identify the minimal binding
BAT element. The binding activity of the different transcripts and the sequence of the
predicted Dab2/BAT element have been summarized.
(B) Secondary structure of the mouse Dab2/BAT (dG = -5.0 Kcal/mol) and ILEI/BAT (dG
= -2.5 Kcal/mol) elements as predicted by the Mfold algorithm. Substituted nucleotide
(U10A) represents a mutant form. ILEI/BAT element was folded under (F 5 0 2)/ (F 9 0
2)/ (P 11 0 2) constraints.

48

Figure 2.9: Uncoupled transcription and translation of ILEI in NMuMG.
(A) Semi-quantitative RT-PCR and (B) immunoblot analyses examining mRNA and
protein expression levels of ILEI in NMuMG cells treated with TGFβ.

Figure 2.10: TGFβ translationally upregulates ILEI expression.
Translocation of ILEI mRNA from the non-polysomal to polysomal pool in control and
TGFβ-stimulated NMuMG cells was analyzed by semi-quantitative RT-PCR of RNA
isolated from each fraction following polysome profiling.
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Figure 2.11: The 33 nt BAT element binds 2 proteins in a TGFβ-dependent fashion
and the binding is highly specific to the BAT element.
(A) X-link analysis was performed with [α-32P]-labeled Dab2/BAT probe (10 fmol) and
S100 cytosolic extract from NMuMG cells treated with TGFβ. The arrows indicate the
positions of two proteins that fail to bind the probe following TGFβ treatment.
(B) Specificity of the BAT element was examined by decoy X-link using [α-32P]-labeled
Dab2/BAT probe and a 2- or 10-fold molar excess (2X or 10X) of unlabeled Dab2/BAT,
ILEI/BAT, and mutant (U10A) Dab2/BAT-M cRNA.
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Figure
2.12:
The
translational
silencing
capacity of the 3’-UTR
element can be conferred to
a heterologous transcript in
vitro.
(A) Schematic representation
of the chimeric luciferase
construct used for the in vitro
translation assays and the
overall procedure adapted for
the experiments.

(B) Proteins in the cytosolic
extract
can
functionally
repress translation. In vitro
translation was performed
using wild-type (top panel)
and
mutant
chimeric
luciferase constructs (bottom
panel) (Luc-Dab2/BAT and
Luc-Dab2/BAT-M)
in
the
presence
of
increasing
amounts
of
unstimulated
cytosolic extracts (50 ng to 10
µg) to assess in vitro
functional translation silencing
activity. Capped, Xenopus
elongation factor-1 (X. EF-1)
cRNA was added to each
reaction as specificity and
loading control.
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Figure 2.13: Translational
silencing conferred by the
Dab2 and ILEI 3’-UTR
elements is relieved by
TGFβ in vitro.
(A) IVT analyses with
chimeric
Luc-Dab2/BAT,
Luc-ILEI/BAT
and
LucDab2/BAT-M shows that
TGFβ treatment relieves
translational
silencing
conferred by the WT and not
the mutant BAT element
following 3 hr of TGFβ
treatment.

(B) Functional specificity of
the BAT element was
examined
by
loss
of
translational inhibition activity
conferred by TGFβ-untreated
cytosolic extract in a decoy
IVT assay using 1-10 fold
(1X-10X) molar excess of
BAT
cRNA
as
cold
competitors.
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Figure 2.14: Translational silencing conferred by the Dab2 and ILEI 3’-UTR
elements is relieved by TGFβ in vivo.
Dual-luciferase assay examining the in vivo translational silencing activity conferred by
the BAT element by co-transfecting with wild-type, mutant (Luc-BAT, Luc-BAT-M) or
luciferase alone (Luc-alone) and CMV-driven renilla luciferase constructs. The firefly
luciferase values were normalized to renilla luciferase values (which were checked for
uniformity to monitor equal transfection efficiency). Results are shown as means ± s.d.
for three independent sets of experiments (n=3), each experiment done in triplicates.
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Figure 2.15: Isolation of the mRNP complex that binds the BAT element.
(A) Purification of mRNP complex (BAT complex) binding to the BAT element by size
exclusion chromatography of unstimulated S100 cytosolic extract (5 mg). Protein content
of chromatographic fractions was quantitated at 280 nm (■) and compared to protein
standards (top line); translation inhibition was quantitated by NIH ImageJ software and
compared to inhibitory capacity of unfractionated, unstimulated S100 extract (▲). The
open and filled bars on the right hand side are quantitative representation of translational
inhibitory activity of unstimulated and TGFβ-treated extracts seen in Fig. 3a (last 2 lanes
on the right side).
(B) IVT assay for translation inhibitory activity of chimeric Dab2/BAT-Luc cRNA using
size exclusion chromatographic fractions.
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Figure 2.16: hnRNP E1 is an integral functional component of the mRNP complex.
Chromatographic fractions (# 36-38) harboring translational silencing activity were
subjected to pull-down with Dab2/BAT cRNA bound to cyanogens bromide (CNBr)activated sepharose beads after pre-clearing with U10A Dab2/BAT-M cRNA.
Precipitated mRNP complex was visualized by silver staining (left panel) and the band
(arrowhead) which migrated similarly to the band that does not bind the BAT element
after TGFβ treatment (shown by arrowhead in right panel) was analyzed by LC-MS.
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Figure 2.17: RNA affinity chromatography identified hnRNP E1 as one of the
proteins binding the BAT element.
(A) IB analysis of chromatographic fractions with α-hnRNP E1 antibody exclusively
detected hnRNP E1 in fractions harboring translational silencing activity.
(B) RNA affinity pull-down and IB analyses using S100 cytosolic extracts for the times
indicated to define the temporal association of hnRNP E1 with the Dab2 and ILEI BAT
element.
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Figure 2.18: hnRNP E1 is required for translational silencing.
(A) In vitro translation with specific immuno-depleted cytosolic extracts confirmed that
hnRNP E1 is a functionally important trigger responsible for the observed translational
silencing. Control cytosolic extracts (S100 fractions) (100 to 400 µg) were immunodepleted with 5 µg of α-hnRNP E1 antibody or 5 µg of mouse pre-immune serum.
Immuno-depleted extracts were assayed for translational silencing activity in vitro using
the chimeric Luc reporter cRNA.
(B) Confirmation of the immuno-depleted status of the cytosolic extracts. Pellets from the
immunodepletion were resolved by SDS-PAGE and immunoblotted with α-hnRNP E1
antibody. Immunodepleted extracts were also probed with α-hnRNP E1 antibody to
confirm their relative immunodepletion of hnRNP E1.
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Figure 2.19: hnRNP E1 interacts with the BAT element in vitro.
IB analyses of GST-hnRNP E1 or GST proteins precipitated in vitro by Dab2/BAT cRNA
(top panel) and ILEI/BAT cRNA (bottom panel).
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Figure 2.20: hnRNP E1 interacts with the BAT element in vivo.
hnRNP E1 interacts with the BAT element in vivo. Immunoprecipitation with α-hnRNP E1
(A) or mouse IgG (B) of cytosolic extracts from NMuMG cells treated with TGFβ for the
times indicated followed by semi-quantitative RT-PCR (using Dab2, ILEI, and β-actin
specific primers) analyses of RNA isolated from the immunoprecipitates to examine in
vivo association of hnRNP E1 with the BAT element. RNA isolated from input extracts
were also analyzed by semi-quantitative RT-PCR (C).
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2.5. Discussion
TGFβ-mediated EMT is an important prerequisite for metastatic
progression (Derynck et al., 2001; Zavadil and Bottinger, 2005; Thiery and
Sleeman, 2006). But the precise mechanism(s) regulating TGFβ-mediated EMT
remain(s) elusive. We now report that TGFβ stimulates translational upregulation
of Dab2 and ILEI expression. A novel 33nt cis-element (TGFβ activated
translation element or BAT element) was identified to be regulating translational
silencing of Dab2 and ILEI. We have purified and identified hnRNP E1 as a
component of the mRNP complex binding to the BAT elements in the 3’-UTRs of
Dab2 and ILEI mRNAs. Prolonged stimulation of TGFβ causes release of hnRNP
E1 from the BAT element allowing their translation. Although TGFβ is known to
cause global translational upregulation by activation of the mTOR pathway
(Lamouille and Derynck, 2007), to our knowledge, this is the first demonstration
of transcript-specific translational activation of transcripts required for EMT by
TGFβ.
Translational Regulation by UTRs Represent a Novel Paradigm for
Regulation of Gene Expression. Regulation of gene expression at the
posttranscriptional level seems to render a more well-defined and rigorous
regulatory checkpoint for cellular processes that governs the development and
homeostasis of cells and tissues (Ruvinsky and Meyuhas, 2006). Concurrently,
deregulation of this regulatory machinery has been implicated in alterations of
cell cycle progression and cell growth associated with stress, inflammation and
carcinogenesis (Standart and Jackson, 1994; Mazumder and Fox, 1999;
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Ruggero and Pandolfi, 2003). Regulatory elements located within the 5’ or 3’
UTRs have been implicated for the translational regulation of different mRNAs.
For

example,

5’-UTR

sequences

control

amino

acid

metabolism

in

Saccharomyces cerevisae (Dever et al., 1992; Hinnebusch, 1994). Similarly,
binding of iron regulatory protein 1 to the ferritin 5’-UTR prevents translational
initiation by inhibiting recruitment of the 40S ribosomal subunit (Muckenthaler et
al., 1998). Interestingly, the 3’-UTRs has assumed more importance as
mediators of transcript-specific translational regulation. In fact, it is now believed
that 3’-UTRs more often contains regulatory sequences than 5’-UTRs (Ostareck
et al., 1997). 3’-UTR mediated translational regulation seems to be important in
developmental regulation in C. elegans, Drosophila, Xenopus, and mammals or
in disease conditions like inflammation (Huarte et al., 1992; Jackson, 1993;
Wickens et al., 1993, 1996; Evans et al., 1994; Curtis et al., 1995; Mazumder and
Fox, 1999). In addition to this, translational regulation is mediated by cooperative
regulation of regulatory elements in the 5’ and 3’-UTR as in the case of
Drosophila male sex lethal-2 (MSL-2) (Beckmann et al., 2005). We have
identified a novel 33nt structural element in the 3’-UTR of two bonafide EMT
inducer transcripts. Structurally, the element forms a 12-nt terminal loop
separated from an asymmetric bulge by a short 3-nt stem and a proximal 7-nt
double-helical stem supports the entire structure. The 33 nt element is sufficient
to mediate translational inhibition of a heterologous chimeric reporter transcript
both in vitro and in vivo.
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We have identified hnRNP E1 as a critical component of the mRNP
complex that binds the 33nt element in the 3’-UTR of Dab2 and ILEI mRNA and
uncouples it from the polysomes in control cells thereby repressing their
translation. hnRNP E1 (also called poly(rC)-binding protein or α-CP1) has been
implicated in the translational regulation and mRNA stability of many transcripts,
including gastrin (Lee et al., 2007), A2 response element (Kosturko et al., 2006),
collagen I, III (Thiele et al., 2004), renin (Morris et al., 2004), folate receptors
(Antony et al., 2004), and 15-lipoxygenase (Ostareck et al., 1997). Recent
studies have revealed that a distinct subset of hnRNP E1 shuttle between the
nucleus and the cytoplasm, suggesting unexpected functions of these protein in
nucleo-cytoplasmic transport and/or in the cytoplasm (Pinol-Roma and Dreyfuss,
1993; Meng et al., 2007). hnRNP E1 preferentially binds to poly(C) regions of
mRNA (Aasheim et al., 1994). As is evident from the sequence of the 33nt
element, it is not poly(C) rich. hnRNP E1 has also been shown to bind poly(U)
stretch (Leffers, 1995), albeit with less affinity. Decoy experiments with a putative
DICE element (containing 2 subunits of the 19 nt DICE element) showed that it
could not compete the binding affinity shown by the 33nt Dab2 element in a UV
crosslinking assay (data not shown). Also, RNA pull down with the 33nt and
DICE synthetic RNAs showed that while the former showed a TGFβ-dependent
temporal association with hnRNP E1, the later associated with hnRNPs E1 and K
in a TGFβ-independent fashion. Hence, it can be rationalized that while the
hnRNP E1 show relatively broad specificity for CU-rich sequences in biochemical
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binding assays (Matunis et al., 1992; Kiledjian et al., 1995), they are exquisitely
discriminatory in their functional specificity (Ostareck et al., 1997).
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CHAPTER III
TGFβ-MEDIATED PHSOPHORYLATION OF hnRNP E1 IS CRITICAL TO
TRANSLATIONAL ACTIVATION OF DAB2 AND ILEI AND INDUCTION OF
EMT

3.1. Abstract
We have earlier shown that TGFβ induces epithelial-mesenchymal
transdifferentiation (EMT) accompanied by cellular differentiation and migration
through

transcript-selective

translational

activation

of

Dab2

and

ILEI.

Heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) binds a structural, 33
nucleotides (nt) TGF beta-activated translation (BAT) element in the 3’-UTR of
disabled-2 (Dab2) and interleukin-like EMT inducer (ILEI) transcripts, and repress
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their translation. We now show that TGFβ activation leads to phosphorylation at
Ser43 of hnRNP E1 by protein kinase Bβ/Akt2, inducing its release from the BAT
element and translational activation of Dab2 and ILEI mRNAs. Modulation of
hnRNP E1 expression or its post-translational modification alters TGFβ-mediated
translational activation of the target transcripts and EMT in vitro and in vivo.
These results suggest the existence of a TGFβ-inducible post-transcriptional
regulon that regulates EMT during development and metastatic progression of
tumors.
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3.2. Introduction
TGFβ-mediated epithelial-mesenchymal transition (EMT), in which cells
undergo a switch from a polarized, epithelial phenotype to a highly motile
fibroblastic or mesenchymal phenotype is fundamental during embryonic
development and can be reactivated in a variety of diseases including fibrosis
and cancer (Derynck et al., 2001; Zavadil and Bottinger, 2005; Bierie and Moses,
2006; Thiery and Sleeman, 2006; Massague, 2008). TGFβ is one of the growth
factors implicated in EMT (Massague, 2008). Disabled-2 (Dab2) (Prunier and
Howe, 2005) and FAM3C or interleukin like EMT inducer (ILEI) (Waerner et al.,
2006) were identified as two candidate genes required for TGFβ-induced EMT.
We

have

earlier

shown

in

Chapter

II

that

heterogeneous

nuclear

ribonucleoprotein E1 (hnRNP E1) binds a structural, 33 nucleotides (nt) TGF
beta-activated translation (BAT) element in the 3’-UTR of disabled-2 (Dab2) and
interleukin-like EMT inducer (ILEI) transcripts, and repress their translation.
Prolonged TGFβ stimulation caused a release of hnRNP E1 from the BAT
elements and concurrent translational activation of Dab2 and ILEI. We next
wanted to investigate the effect of TGFβ stimulation on hnRNP E1 and
mechanism by which TGFβ was promoting translational activation of Dab2 and
ILEI.
Here, we report identification of the single site of hnRNP E1
phosphorylation responsible for its release from the mRNP complex and
concurrent activation of Dab2 and ILEI translation in TGFβ-treated NMuMG and
EpRas cells. Additionally, we show that TGFβ activates a cascade in which
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protein kinase Bβ/Akt2 is activated and subsequently phosphorylates hnRNP E1
at Ser43 residue, culminating in its release from the transcripts and concurrent
translational activation of the two EMT inducers. Remarkably, ectopic
overexpression of hnRNP E1 in NMuMG cells results in total inhibition of TGFβmediated EMT, whereas shRNA-mediated silencing of hnRNP E1 renders
mesenchymal properties to NMuMG cells irrespective of TGFβ treatment. Reintroduction of wild type, but not a Ser43 to Ala mutant of human hnRNP E1 can
rescue the epithelial phenotype of the shRNA-silenced hnRNP E1 cells. We also
report that modulation of hnRNP E1 expression levels or its phosphorylation
status modulates migration and invasive potential in in vitro and in vivo xenograft
assays. The autocrine response of cells to TGFβ-induced Akt2 activation and
subsequent translational activation of EMT inducer transcripts may represent a
novel mechanism through which the increased TGFβ expression in tumor cells
contributes to cancer progression.

67

3.3. Materials and Methods
3.3.1. Reagents.
Rabbit reticulocyte lysate, methionine free amino acids, RNasin and
RiboMAX Large Scale RNA Production kit were purchased from Promega.
MAXIscript, mMESSAGE mMACHINE T7 Ultra kits, siPORT and pSilencerTM neo
vector were purchased from Ambion. Primers and oligos were purchased from
Integrated DNA technologies. Translation grade [35S]-methionine and [γ-32P]-ATP
were purchased from Perkin Elmer Life Sciences. LY294002 was obtained from
Alexis-Biochemicals, SB431542 from Sigma and Akt IV inhibitor from EMD
Biosciences. Mouse α-hnRNP E1 was from Novus Biologicals, rabbit α-hnRNP
E1 was from Lifespan Biosciences. Antibodies against phospho-Akt (Ser-473),
total Akt, Akt1, Akt2, Akt3, phospho-Akt substrate (RXRXXS/T) (110B7E), PAK1,
vimentin and recombinant GSK-3 fusion protein and recombinant Akt1 and Akt2
kinase were purchased from Cell Signaling Technology. α-FAM3C and Ncadherin antibodies were obtained from Abcam, α-phospho-serine (clone PSR45) antibody from Sigma-Aldrich, and α-ZO-1 from Zymed Laboratories. α-Hsp90
(H-114), α-p-Threonine (H-2) and normal mouse and rabbit IgG were purchased
from Santa Cruz Biotechnology. Secondary antibodies Alexa Flour 568
phalloidin, Alexa Flour 468 and Oregon Green 468 were purchased from
Molecular Probes, Invitrogen. Vectashield mounting medium with DAPI was
purchased from Vector Laboratories.
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3.3.2. Cell culture and treatments.
TGFβ2 was a generous gift from Genzyme Inc. and was used at a final
concentration of 5 ng/ml. NMuMG cells were cultured as described previously
(Prunier and Howe, 2005). EpRas were maintained in Dulbecco’s modified
Eagle’s

medium

supplemented

with

10%

fetal

bovine

serum

and

antibiotics/antimycotics. For stimulation with insulin, the cells were maintained in
a serum-free media for 6 hours and were then stimulated with 10 nM insulin.
Where indicated, cells were treated with DMSO (vehicle, control) or 10 µM of
SB431542, LY294002 or Akt IV 30 min before TGF treatment.
3.3.3. Plasmids construction and protein expression.
For construction of the Luc-Dab2/BAT, Luc-Dab2/BAT-M mutant and LucILEI/BAT, luciferase cDNA derived from pGL3-b vector was cloned into pcDNA3.
A linker region containing 5’-EcoR1-Pac1-EcoRV-Nco-1-Xho-1-Xba-1 was
inserted into the vector downstream of the luciferase gene (pCMV-LL). Synthetic
Dab2/BAT, Dab2/BAT-M and ILEI/BAT were generated with 5’-EcoR1 and 3’Xba-1 sites (pCMVLuc-Dab2/BAT, pCMVLuc-Dab2/BAT-M, pCMVLuc-ILEI/BAT).
The GST-hnRNP E1 construct was a kind gift from Dr. R. Kumar and has
been previously described (Meng et al., 2007). The GST clones were maintained
in E. coli BL21 (DE3)pLysS for expression. For expression, the protocol as
described before was followed (Meng et al., 2007). The mouse pCMV14-hnRNP
E1-FLAG and psiRNA-hH1neo-mouse hnRNP E1 (shRNA against hnRNP E1
ORF) were kind gifts from Dr. T. Kobayashi and has been previously described
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(Nishinakamura et al., 2007). pSilencer neo-shRNA-mouse hnRNP E1-3’-UTR
(shRNA against 3’UTR of hnRNP E1) was constructed by annealing shRNA
template oligonucleotides (target selected through engine at Ambion and cloned
into pSilencer neo vector (refer to Table I for oligonucleotide sequences). The
S43A mutation was introduced into GST-hnRNP E1 and pCMV14-hnRNP E1FLAG using Quick Change Site Directed Mutagenesis Kit, Stratagene (refer to
Table I for primer sequence). pSUPER-Dab2si construct has been generated in
the lab and described previously (Prunier and Howe, 2005). The ILEI siRNA (m),
a pool of 3 target-specific 19-25 nt. siRNAs, and control siRNA-A, a non-targeting
20-25 nt. siRNA, were brought from Santa Cruz Biotechnology Inc.
3.3.4.

Preparation

of

cell

lysates,

immunoblot

analysis,

immunoprecipitation and immunodepletion.
For immunoprecipitation and immunoblot analysis, cells were lysed in
buffer D and immunoprecipitation carried out as previously described (Hocevar et
al., 1999).
3.3.5. Preparation of cytosolic extract (S100 Fraction).
S100 fractions were prepared from control and TGFβ-treated NMuMG
cells as previously described (Mazumder and Fox, 1999) with minor
modifications. Briefly, the buffer used for cytosolic extraction contained 20 mM
Hepes (pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM
DTT and protease inhibitor cocktail (Roche) (Hampton et al., 1998).
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3.3.6. In vitro luciferase assay.
In vitro luciferase assay was performed as previously described
(Mazumder and Fox, 1999).
3.3.7. In vitro kinase assays.
In vitro kinase assays were performed using both recombinant Akt kinase
and kinases immunoprecipitated from whole cell lysates as described previously
(Qi et al., 2003).
3.3.8. Immunofluorescence.
Protocol followed was previously described (Lamouille and Derynck, 2007)
with minor modifications. The primary antibodies used were: anti-E-cadherin
(diluted 1:400), anti-ZO-1 (diluted 1:200). The secondary antibodies used were
Alexa Flour 468 (diluted 1:1500) or Oregon Green 468 (diluted 1:1500). The
slides were then incubated in Alexa Fluor 568 Phalloidin (diluted 1:1000) for 20
min at room temperature to visualize actin filaments. The slides were mounted in
Vectashield with DAPI and visualized using a Leica DMIRB inverted microscope
(Leica Microsystems) equipped with Retiga Exi Cooled CCD Camera (Q Imaging,
Burnby). Excitation at 490 nm and standard fluorescent filter were used to take
images.
3.3.9. Cell proliferation assay.
105 cells/well of a particular cell type were plated in triplicates in a 6-well
tissue culture plate. Cells were trypsinized and resuspended in 1 ml of media,
before being counted through a hemocytometer chamber upto 12 days following
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initial seeding. The experiment was repeated thrice and the results are
represented as means ± s.d.
3.3.10. Anchorage-independent growth assay (soft-agar colony formation
assay).
Anchorage-independent growth assay was performed as described earlier
(Pietenpol et al., 1989). Approximately 104 cells were suspended in 2 ml of 0.4%
soft-agar in DMEM containing 10% fetal bovine serum and were overlaid on 2 ml
of 0.8% soft agar ± TGFβ in the same medium in 35-mm-diameter dishes. Each
cell line was tested in triplicate wells. Colonies were visualized under an inverted
light microscope after 3 weeks. Data are represented as means ± s.d. of single
experiment done in triplicates.
3.3.11. Wound healing (migration) assay.
Wound healing assay was done as described previously (Lamouille and
Derynck, 2007) with brief modifications. Cell monolayers were wounded with a
plastic tip after 24 hr of seeding and images obtained using a phase-contrast
microscope at x5 magnification. The cells were incubated in a humidified
chamber with 5% carbon dioxide ± TGFβ for 24 hr at 37°C before being
photographed again at x5 magnification.
3.3.12. Invasion assay.
Cell invasion assay was done using CytoSelect™ 96-well Cell Invasion
Assay Kit (Cell Biolabs, San Diego, CA) as per the manufacturer’s protocol. The
experiment was done with the addition of the 2 x 105 cells to the membrane
chamber and in the absence and presence of serum and TGFβ in the feeder tray.
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Cell invasion was assayed by using the provided cell lysis buffer and CyQuant®
dye fluorimetrically at 480 nm/520 nm. The data is represented as means ± s.d.
of three independent experiments.
3.3.13. Experimental tumorigenesis and metastasis assay.
Tumor formation and metastatic ability of parental NMuMG cells and the
different NMuMG clones that were generated were determined by sub cutaneous
injection of 105 cells on the hind flank (each side) into six weeks old BalbC
athymic nude mice (nu/nu), according to approved protocols of Institutional
Animal Care and Use Committee (IACUC), Cleveland Clinic. Tumor volume
(mm3) was determined by using the standard formula a2 x b/2, where ‘a’ is the
width and ‘b’ is the length of the horizontal tumor perimeter, determined thrice a
week with a vernier caliper. Twelve animals were used for each cell type but the
data represented here is representative of three animals per group as the other
animals have still not been harvested. The data is represented as mean ± s.e.m.
After determination of tumor weight and/or photography, excised tumors
and lung, liver and colon tissues were fixed with paraformaldehyde (4%, 18 hr,
4°C) and post fixed (70% ethanol, 16 hr) before dehydration and paraffin
embedding. Paraffin sections were stained with hematoxylin/eosin according to
standard protocols.
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3.4. Results
3.4.1. TGFβ
β driven phosphorylation of hnRNP E1 releases the translational
silencing
We observed that pre-treatment with calf intestinal alkaline phosphatase (CIP)
renders translational silencing activity to TGFβ-treated extracts, suggesting
necessity of TGFβ-dependent phosphorylation for the release of translational
inhibition (Fig. 3.1). We next evaluated TGFβ-mediated phosphorylation of
hnRNP E1 as a possible mechanism for loss of translational silencing following
TGFβ treatment. TGFβ induced phosphorylation of hnRNP E1 at serine
residue(s), with phospho-hnRNP E1 detected as early as 30 min after TGFβ
treatment and maximally at 3 and 6 hr (Fig. 3.2).
3.4.2. Akt2 phosphorylates hnRNP E1 in TGFβ
β -stimulated NMuMG cells
Sequence analysis revealed that mouse hnRNP E1 contains an Akt
consensus phosphorylation site at Ser43 (Fig. 3.3). We therefore postulated that
hnRNP E1 might be a substrate of Akt. As shown by others (Bakin et al., 2000;
Kattla et al., 2008; Kato et al., 2009), TGFβ was found to activate Akt (Fig. 3.4);
furthermore, using a substrate-directed phospho-specific antibody, Akt-mediated
phosphorylation of hnRNP E1 was demonstrated to be TGFβ-dependent (Fig.
3.5A). Use of PI3K inhibitor, LY294002 showed robust inhibition of TGFβ-induced
phospho-hnRNP E1 (Fig. 3.5B) and attenuated release of hnRNP E1 from the
Dab2/BAT element following TGFβ treatment (Fig. 3.5 C). Selective inhibition of
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either TGFβ signaling with the type I receptor inhibitor SB-431542 and of Akt
kinase with Akt IV inhibited TGFβ-dependent hnRNP E1 phosphorylation and Akt
activation, without affecting total Akt levels (Fig. 3.6), confirming the direct
correlation between TGFβ signaling and hnRNP E1 phosphorylation. Importantly,
inhibiting either TGFβ signaling (with SB-431542) or Akt (with LY294002 and Akt
IV) also inhibited the reversal of translational silencing (Fig. 3.6, bottom panel),
hence suggesting a direct relationship between hnRNP E1 phosphorylation and
translational activation post-TGFβ stimulation.
Additionally, recombinant Akt phosphorylated GST-hnRNP E1, but not
GST in an in vitro kinase assay (Fig. 3.7A) and in vitro Akt-phosphorylated GSThnRNP E1 no longer bound the Dab2/BAT element (Fig. 3.7B). In vivo
phosphorylation

of

hnRNP

E1

by

Akt

was

investigated

by

using

immunoprecipitated Akt (pan Akt antibody) as the kinase source to phosphorylate
hnRNP E1. TGFβ activated Akt was capable of phosphorylating a WT hnRNP E1
fusion protein but not a S43A mutant, confirming Ser43 as the Akt
phosphorylation site (Fig. 3.8). Since p21-activated kinase 1 (PAK1) can
phosphorylate hnRNP E1 on Thr60 and Thr127 (Meng et al., 2007), we
examined the phosphorylating effects of PAK1 following TGFβ stimulation. PAK1
immunoprecipitates phosphorylated both WT and the S43A mutant of hnRNP E1
indicating that phosphorylation at Ser43 is specific to TGFβ signaling (Fig. 3.8).
We investigated if phosphorylation of hnRNP E1 by activated Akt was
specific to TGFβ stimulation. Both insulin (previously shown to activate Akt (Datta
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et al., 1999; Brazil et al., 2001) and TGFβ induced Akt activation in NMuMG cells,
albeit with different kinetics (Fig. 3.9A, top and middle panels), but insulinmediated Akt activation did not result in hnRNP E1 phosphorylation (Fig. 3.9A,
bottom panel). Insulin stimulation also failed to induce either Dab2 or ILEI protein
expression (Fig. 3.9B) or reverse in vitro translation silencing activity (Fig. 3.10).
To determine whether different Akt isoforms (Kato et al., 2007) were activated by
insulin and TGFβ, we immunoprecipitated lysates with the three Akt isoforms,
Akt1, Akt2 and Akt3 and probed them with α-p-Akt (pSer473) antibody (Fig.
3.11). Insulin selectively activated Akt1 (Fig. 3.11A, top panel), whereas TGFβ
activated Akt2 (Fig. 3.11A, third panel). Neither insulin nor TGFβ activated Akt3
(data not shown). Similar isoform specific Akt activation was observed in EpRas
cells (Fig. 3.11B). Substrate specificity of Akt2 for hnRNP E1 was further
demonstrated by in vitro kinase assay of GST-hnRNP E1 by using
immunoprecipitated Akt2 or Akt1 from TGFβ-treated cells as the kinase source to
phosphorylate hnRNP E1. TGFβ activated Akt2, and not Akt1, was only capable
of phosphorylating the GST-hnRNPE1 protein in vitro (Fig. 3.12). The fact that
immunoprecipitated Akt1 fails to phosphorylate hnRNP E1 suggests that it is not
being activated by TGFβ since both Akt1 and Akt2 share the same
phosphorylation target sequence and purified Akt1 and Akt2 can phosphorylate
GST-hnRNP E1 in vitro (data not shown). Hence, phosphorylation of hnRNP E1
on Ser43 by TGFβ-activated Akt2 kinase disrupts its binding to the BAT element
and causes loss of translation silencing.
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3.4.3. Modulating hnRNP E1 levels in NMuMG Cells directly affects the
translational regulatory mechanism and EMT
We investigated whether modulating hnRNP E1 levels altered TGFβmediated EMT. We stably overexpressed (E23) or silenced (E2KD) hnRNP E1 in
NMuMG cells (Fig. 3.13), and compared effects on EMT. NMuMG cells
underwent EMT after TGFβ treatment (24 hr), while the process was blocked or
constitutively active in E23 and E2KD cells, respectively (Fig. 3.14). Expression
of Dab2, ILEI and mesenchymal cell markers N-cadherin and vimentin were
constitutively active in E2KD cells and completely blocked in E23 cells (Fig.
3.15). Parental NMuMG cells showed classical mesenchymal cells features
following a 24 hr TGFβ treatment, including loss of E-cadherin expression, actin
reorganization at cell junctions and re-localization of ZO-1 from tight junctions
(Massague, 2008), whereas such changes were absent in E23 cells and visible
in E2KD control cells, demonstrating that hnRNP E1 is an important component
of the TGFβ-mediated translational regulation of Dab2 and ILEI, and EMT (Fig.
3.16).
To confirm that hnRNP E1, and specifically the Ser43 phosphorylation of
hnRNP E1, was regulating TGFβ-mediated EMT, we knocked in either WT
(KIWT6 cells) or a phospho-mutant (KIM2 cells) version of hnRNP E1 into stable
hnRNP E1 knockdown cells, SH14 (shRNA directed against the 3’-UTR of
hnRNP E1) (Fig. 3.17A). Stable knockdown of hnRNP E1 rendered
mesenchymal phenotype to cells even in the absence of TGFβ, whereas knockin of either the WT or S43A mutant hnRNP E1 rescued the epithelial phenotype
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(Fig. 3.17B). TGFβ stimulation caused EMT in KIWT6, but blocked it in KIM2
cells (Fig. 3.17B). Correspondingly, TGFβ-induced hnRNP E1 phosphorylation in
KIWT6 cells, but not in KIM2 cells (Fig. 3.18, top panel) further confirming Ser43
as the phosphorylation site. In both KIWT6 and KIM2 cells, TGFβ activated Akt
like in parental cells (Fig. 3.18, third panel). Vimentin, N-cadherin, Dab2 and ILEI
expression corroborated the morphological analysis (Fig. 3.19). Cytosolic
extracts from these cells confirmed that Ser43 phosphorylation of hnRNP E1 also
regulates translational silencing activity (Fig. 3.20A). In addition, RNA pull-down
with Dab2/BAT cRNA showed that hnRNP E1 is not released from the BAT
element following TGFβ treatment in KIM2 cells as in NMuMG and KIWT6 cells
(Fig. 3.20B). These results confirm that TGFβ-activated Akt2 phosphorylates
hnRNP E1 at Ser43, a prerequisite for its release from the BAT element and
concurrent translational activation of Dab2 and ILEI mRNAs.
Since Dab2 and ILEI are required but not sufficient to induce EMT it is
difficult to precisely define their

function

downstream of

hnRNP E1.

Overexpression of Dab2 or ILEI alone does not induce any morphological
changes associated with EMT (Fig. 3.21 & data not shown) or up-regulate Ncadherin expression (Fig. 3.22) independent of TGFβ stimulation. We postulated
that if Dab2 and ILEI are required for EMT, then silencing the expression level of
either one will rescue epithelial cell properties in the SH14 cells. si-RNA
mediated silencing of either Dab2 or ILEI attenuated induction of EMT as evident
by loss of expression of mesenchymal cell markers, N-cadherin and vimentin
(Fig. 3.23) and loss of morphological features associated with mesenchymal cells
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(data not shown) Cumulatively, these results clearly support our hypothesis that
the role of hnRNP E1 on EMT is mediated through induction of Dab2 and ILEI
and that they are critical mediators of EMT.
3.4.4. Modulating hnRNP E1 levels in NMuMG Cells or its derivative clones
affect in vitro migration and invasive capacity
Based on our model, and as we observed with knock-down and
reconstituted NMuMG cells, we predict that the S43A hnRNP E1 mutant will not
be released from the BAT element of Dab2, ILEI, and other EMT inducer
mRNAs, resulting in lower rates of proliferation, invasion, migration, and soft agar
growth. We functionally analyzed the parental NMuMG and the derivative clones
by measuring changes in the proliferative, tumorigenic, migration and invasive
potential using a combination of in vitro assays including proliferation rates in
monolayer, colony formation on soft agar, wound healing (migration) and
invasion assays, respectively. Knock-down of hnRNP E1 (SH14 cells) showed an
increase in the proliferation (Fig. 3.24), soft agar growth (Fig. 3.25), migration
(Fig. 3.26) and invasion of the cells (Fig. 3.27). Reconstitution with WT hnRNP
E1 (KIWT6 cells), did not result in any significant difference in these parameters
compared to the parental NMuMG cells. Reconstitution with S43A mutant hnRNP
E1 (KIM2 cells) resulted in attenuation in these indexes.
3.4.5. Modulating hnRNP E1 levels in NMuMG Cells or its derivative clones
affect in vivo tumor formation and metastasis
Based on the in vitro findings, we performed preliminary xenograft tumor
growth studies in which we sub cutaneously injected either parental NMuMG
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cells, the E23 overexpressing, or the SH14 knock-down clones into the hind flank
of Balbc athymic nude mice (12 mice/cell types). A representative animal from
each group is depicted in Fig. 3.28, demonstrating that parental NMuMG (right)
form small orthotropic tumors (36 days post injection), whereas E23 cells
(middle) do not develop any detectable tumors. In contrast, animals injected with
the hnRNP E1 knock-down SH14 cells (left) develop tumors with a mean volume
of 153 ± 46 mm3. Fig. 3.29 presents graphically the data of tumor growth over
time for the 3 different cell types. Interestingly, we observed that animals injected
with the SH14 knock-down cells metastasized to lung (Fig. 3.30A) and liver (Fig.
3.30B). We did not observe any metastatic lesions in the colon (data not shown).
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Figure 3.1: TGFβ-mediated phosphorylation is involved in loss of translational
silencing.
IVT assay of Luc-Dab2/BAT cRNA with unstimulated and 24 hr TGFβ-treated cytosolic
extracts in the presence and absence of phosphatase. Where indicated, the cytosolic
extracts were pre-treated with calf intestinal phosphatase (CIP), CIP and sodium
orthovanadate, or heat-denatured CIP before addition to the IVT assay.

Figure 3.2: TGFβ phosphorylates hnRNP E1.
IB analysis of immunoprecipitates derived from NMuMG WCLs with α-phospho-serine
(p-ser) antibody (top panel) and α-hnRNP E1 antibody (bottom panel) to examine TGFβdependent hnRNP E1 phosphorylation.
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Figure 3.3: Schematic representation of the Akt consensus phosphorylation site
at Ser43 in the KH1 domain of hnRNP E1.

Figure 3.4: TGFβ
β activates Akt kinase.
NMuMG cells were treated with TGFβ for the times indicated and WCLs were prepared
and analyzed by immunoblotting with α-phospho-Akt antibody (top panel). The blot was
stripped and re-probed with α-Akt antibody (bottom panel).

82

Figure 3.5:
stimulation.

Akt is the kinase that phosphorylates hnRNP E1 after TGFβ

(A) IB analysis of α-hnRNP E1 immunoprecipitates derived from NMuMG WCLs were
probed with the phospho-Akt substrate antibody that recognizes the RXRXXpS/pT motif.
(B) IB analysis of α-hnRNP E1 immunoprecipitates from LY294002 treated and
untreated WCLs with α-phospho-serine (p-ser) antibody (top panel) and α-hnRNP E1
antibody (bottom panel) to confirm Akt as the kinase.
(C) RNA affinity pull-down and IB analysis of cytosolic extracts from unstimulated and
LY294002-treated cells to examine temporal association of hnRNP E1 and the BAT
element.

Figure 3.6: Akt is the kinase for hnRNP E1 and Akt-mediated phosphorylation of
hnRNP E1 is required for reversal of translational silencing.
IB analysis of immunoprecipitates (with α-hnRNP E1) (top panel) and WCLs (b, middle
panels) derived from NMuMG cells treated with SB-431542, LY294002, and Akt IV to
further confirm Akt as the kinase and the TGFβ-dependency of the hnRNP E1
phosphorylation event. IVT assay of Luc-Dab2/BAT with cytosolic extracts to examine
the relationship between hnRNP E1 phosphorylation and de-repression of translational
inhibition (lower panel).
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Figure 3.7: Phosphorylation of hnRNP E1 by TGFβ-mediated activation of Akt
disrupts its binding to the BAT element.
(A) Akt phosphorylates hnRNP E1 in vitro. Increasing amounts of recombinant Akt
kinase was incubated with 5 µg of GST-hnRNP E1 or GST in the presence of [γ-32P]ATP. The kinase reaction products were resolved by SDS-PAGE, and phosphorylation
was detected by autoradiography.
(B) Phosphorylated hnRNP E1 does not bind the BAT element. Increasing amounts of
phosphorylated-GST-hnRNP E1 protein was subjected to pull-down with Dab2/BAT
cRNA. The precipitates and the supernatants post pull-down were analyzed by IB.
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Figure 3.8: Phosphorylation of hnRNP E1 at serine-43 by TGFβ
β-mediated
activation of Akt.
Akt phosphorylates hnRNP E1 at Ser43. Activated kinases were recovered by anti-p-Akt
(pSer473) or PAK1 immunoprecipitation and incubated with 5 µg of GST-hnRNP E1 or
serine-43-alanine (S43A) mutant GST-hnRNP E1 in the presence of [γ-32P]-ATP. The
kinase reaction products were detected by autoradiography. Coomassie stain (bottom
panel) reveals equal amount of GST-hnRNP E1 was present in each reaction.
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Figure 3.9: TGFβ stimulation, and not insulin stimulation induces Dab2 and ILEI
protein expression.
(A) IB analysis of WCLs derived from NMuMG cells post insulin and TGFβ stimulation to
examine insulin and TGFβ-mediated Akt activation (top panel). IB analysis of
immunoprecipitates derived from NMuMG WCLs with α-phospho-serine (p-ser) antibody
(bottom panel) to examine insulin and TGFβ-dependent hnRNP E1 phosphorylation.
(B) IB analysis of WCLs derived from NMuMG cells post insulin and TGFβ stimulation to
examine insulin and TGFβ-mediated induction of Dab2 and ILEI expression.
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Figure 3.10: TGFβ stimulation, and not insulin stimulation induces loss of
translational silencing.
IVT analysis of chimeric luciferase transcripts in the presence of cytosolic extracts made
from insulin or TGFβ treated NMuMG cells for the indicated times.

87

Figure 3.11: TGFβ causes isoform specific activation of Akt2 in NMuMG and
EpRas cells.
(A) IB analysis of Akt1 and Akt2 immunoprecipitates derived from NMuMG WCLs with αphospho-Akt (pS473) antibody to examine insulin and TGFβ-dependent isoform specific
Akt activation.
(B) Isoform specific Akt activation is not cell type specific. WCLs post-TGFβ and insulin
stimulation was prepared from EpRas cells and immunoprecipitated with α-Akt1 or αAkt2 and the blot was probed with α-p-Akt (pS473) antibody.
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Figure 3.12: TGFβ activated Akt2 specifically phosphorylates hnRNP E1.
Activated Akt1 or Akt2 was recovered by anti-Akt1 or anti-Akt2 immunoprecipitation
following TGFβ stimulation and incubated with 5 µg of GST-hnRNP E1 in the presence
of [γ-32P]-ATP.
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Figure 3.13: Confirmation of ectopic overexpression and sh-RNA-mediated
silencing of hnRNP E1.
IB analysis of WCLs derived from wild-type (WT, NMuMG), stable FLAG-hnRNP E1
overexpressing (E23) and stable shRNA-mediated hnRNP E1 knockdown (E2KD;
harboring shRNA directed against the ORF) NMuMG cells to confirm overexpression
and knockdown of hnRNP E1, respectively. (Endo represents the endogenous hnRNP
E1 band; FL represents the flagged-tagged hnRNP E1 band).
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Figure 3.14: Modulation of hnRNP E1 expression alters sensitivity of NMuMG cells
to TGFβ-induced EMT.
Phase contrast images of unstimulated and TGFβ-treated (24 hr) WT, E23 and E2KD
cells examining morphological changes post TGFβ-stimulation. Images were taken at
10X magnification.
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Figure 3.15: Modulation of hnRNP E1 expression alters expression of Dab2 and
ILEI and induction of mesenchymal cell markers.
IB analysis monitoring Dab2, ILEI, N-cadherin, vimentin and β-actin protein levels in WT,
E23 and E2KD cells treated with TGFβ for the times indicated.
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Figure 3.16: hnRNP E1 expression levels regulate sensitivity of NMuMG cells to
TGFβ-induced EMT.
Immunofluorescence of E-cadherin, ZO-1, F-actin in unstimulated and TGFβ-treated (24
hr) WT, E23 and E2KD cells. DAPI was used to stain the nuclei. Images were obtained
at original magnification of 63X. Scale bars, 50 µm.
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Figure 3.17: Modulation of hnRNP E1 phosphorylation changes sensitivity of
NMuMG cells to TGFβ-induced EMT.
(A) IB analysis of WCLs derived from wild-type (WT), stable shRNA-mediated hnRNP E1
knockdown (SH14; harboring shRNA directed against the 3’-UTR), stable knock-in of
wild-type FLAG-hnRNP E1 expressing (KIWT6) and stable knock-in of S43A mutant
FLAG-hnRNP E1 expressing (KIM2) NMuMG cells to confirm knockdown and reexpression of hnRNP E1, respectively.
(B) Phase contrast images of unstimulated and TGFβ-treated (24 hr) SH14, KIM2 and
KIWT6 cells examining morphological changes post TGFβ-stimulation. Images were
taken at 10X magnification.
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Figure 3.18: In vivo validation of Ser43 as the hnRNP E1 phosphorylation site.
WCLs derived from NMuMG, KIM2 and KIWT6 cells were immunoprecipitated with αhnRNP E1 antibody and analyzed by IB with α-phospho serine antibody (top panel) and
α-hnRNP E1 antibody (second panel). TGFβ-dependent Akt activation analyzed by IB
analysis of WCLs derived from NMuMG, KIWT6 and KIM2 cells treated with TGFβ for
the times indicated (third and bottom panel).
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Figure 3.19: Modulation of phosphorylation of hnRNP E1 expression alters
expression of Dab2 and ILEI and induction of mesenchymal cell markers.
IB analysis examining Dab2, ILEI, N-cadherin, vimentin and β-actin protein levels in cells
treated with TGFβ for the times indicated.
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Figure 3.20: Modulation of phosphorylation of hnRNP E1 expression alters
reversal of translational silencing with TGFβ and temporal association of hnRNP
E1 with the BAT element.
(A) IVT and (B) RNA pull-down assays with cytosolic extracts from SH14, KIWT6 and
KIM2 cells treated with TGFβ for the times indicated to examine translational silencing of
chimeric Luc-Dab2/BAT cRNA and temporal association of the modified hnRNP E1 with
the Dab2/BAT cRNA, respectively.
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Figure 3.21: Dab2 is required, but not sufficient for TGFβ-induced EMT.
Phase contrast images of unstimulated and TGFβ-treated (24 hr) NMuMG/Dab2 cells
(NMuMG cells overexpressing Dab2) examining morphological changes post TGFβstimulation. Images were taken at 10X magnification.

Figure 3.22: Ectopic Dab2 overexpression in NMuMG cells does not induce
expression of mesenchymal cell marker.
WCLs made from NMuMG/Dab2 cells were probed with α-mouse Dab2 and α-rabbit Ncadherin antibodies. One of the blots was stripped and re-blotted with α-rabbit Hsp90
antibody as a loading control.
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Figure 3.23: Role of hnRNP E1 on EMT is mediated by Dab2 and ILEI.
IB analysis of WCLs derived from SH14 cells, un-transfected or transiently transfected
with ILEI, Dab2 or control-A siRNA to confirm knockdown of Dab2 and ILEI, respectively
(first and second panel, respectively). IB analysis examining N-cadherin, vimentin and
Hsp90 protein levels in these cells (third, fourth and bottom panel, respectively).
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Figure 3.24: shRNA-mediated silencing of hnRNP E1 results in increased
proliferation of NMuMG cells.
105 cells/well were seeded in triplicates in 6-well tissue culture plates. Cells were
trypsinized and resuspended in 1 ml of media, before being counted through a
hemocytometer chamber upto 12 days following initial seeding. The experiment was
repeated thrice and the results are represented as means ± s.d.
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Figure 3.25: shRNA-mediated silencing of hnRNP E1 in NMuMG cells renders
anchorage independent growth.
104 cells were suspended in 2 ml of 0.4% soft-agar in DMEM containing 10% fetal
bovine serum and were overlaid on 2 ml of 0.8% soft agar ± TGFβ in the same medium
in 35-mm-diameter dishes. Each cell line was tested in triplicate wells. Data are
represented as means ± s.d. of single experiment done in triplicates.
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Figure 3.26: Modulating hnRNP E1 levels in NMuMG Cells or its derivative clones
affect in vitro migration capacity.
Cell monolayers were wounded with a plastic tip after 24 hr of seeding and images
obtained using a phase-contrast microscope at x5 magnification (Control, 0h). The cells
were incubated in a humidified chamber with 5% carbon dioxide ± TGFβ for 24 hr at
37°C before being photographed again at x5 magnification (Control, 24h, TGFβ, 24h).
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Figure 3.27: Modulating hnRNP E1 levels in NMuMG Cells or its derivative clones
affect in vitro invasion capacity.
The experiment was done with the addition of the 2 x 105 cells to the membrane
chamber and in the absence and presence of serum and TGFβ in the feeder tray. Cell
invasion was assayed by using the provided cell lysis buffer and CyQuant® dye
fluorimetrically at 480 nm/520 nm. The data is represented as means ± s.d. of three
independent experiments.
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Figure 3.28: Modulating hnRNP E1 levels in NMuMG Cells or its derivative clones
affect in vivo tumor formation.
105 cells were sub cutaneously injected on the hind flank (each side) into six weeks old
BalbC athymic nude mice (nu/nu), according to approved protocols of Institutional
Animal Care and Use Committee (IACUC), Cleveland Clinic.
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Figure 3.29: Tumors formed from SH14 cells showed steady tumor growth.
Tumor volume (mm3) was determined by using the standard formula a2 x b/2, where ‘a’ is
the width and ‘b’ is the length of the horizontal tumor perimeter, determined thrice a week
with a vernier caliper. The data represented here is representative of three animals per
group. The data is represented as mean ± s.e.m.
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Figure 3.30: Tumors formed from SH14 cells showed metastatic progression to
lung and liver tissues.
Excised tumors and lung, liver and colon tissues were fixed with paraformaldehyde (4%,
18 hr, 4°C) and post fixed (70% ethanol, 16 hr) before dehydration and paraffin
embedding. Paraffin sections were stained with hematoxylin/eosin according to standard
protocols. Images were obtained at 40X magnification.
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3.5. Discussion
We have identified a transcript-selective translational regulation pathway
by which TGFβ modulates expression of mRNAs required for EMT. TGFβ
activates a kinase cascade terminating in phosphorylation of Ser43 of hnRNP
E1, by isoform-specific stimulation of protein kinase Bβ/Akt2, inducing its release
from the BAT element and loss of translational silencing of Dab2 and ILEI
mRNAs. Modulation of hnRNP E1 expression, or of its Ser43 site, alters TGFβmediated loss of translational silencing and EMT. Additionally, modulation of
hnRNP E1 levels significantly alters the in vitro and in vivo proliferation,
tumorigenic and metastatic potential of the NMuMG cells.
Translational

regulatory

phosphorylation-dependent

pathways

regulation.

are

Global

laced

with

examples

of

translational

regulation

is

regulated by phosphorylation of eIF2α, eIF4B, eIF4E and eIF4G (Dever, 2002;
Raught et al., 2004). On the other hand, trans factor-mediated, e.g., hnRNP K,
EPRS, maskin, L13a, phosphorylation has been shown to be important in
transcript-selective translational regulation (Ostareck-Lederer et al., 2002;
Sampath et al., 2004; Barnard et al., 2005; Mukhopadhyay et al., 2008). hnRNP
E1 has been shown to exist in both phosphorylated and unphosphorylated forms
(Leffers, 1995; Meng et al., 2007) and it has been predicted that the
phosphorylated form has comparatively less RNA binding capacity (Leffers,
1995). p21 activated kinase 1 (PAK1) has been previously shown to be
constitutively associated with hnRNP E1 and regulate its RNA binding activity
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(Meng et al., 2007). Here, we have identified a cascade whereby TGFβ activates
Akt2, which in turn is responsible for the single site phosphorylation of hnRNP E1
at serine 43. This is the first evidence of isoform specific Akt activation by TGFβ
and Akt2-mediated phosphorylation of hnRNP E1, and confirms recent findings
that Akt2 is involved in promoting EMT, invasiveness and metastasis (Irie et al.,
2005). We also show that hnRNP E1 phosphorylation is responsible for its
release from the mRNP complex and concurrent activation of Dab2 and ILEI
translation in TGFβ-treated NMuMG and EpRas cells.
The autocrine response of cells to TGFβ-induced Akt activation and
subsequent translational activation of EMT inducer transcripts may represent a
novel mechanism through which the increased TGFβ expression in tumor cells
contributes to cancer progression and provides avenues for novel anti-cancer
therapeutic strategies.
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CHAPTER IV
GENOME-WIDE EXPRESSION PROFILING REVEALS hnRNP E1 MEDIATES
TGFβ-INDUCED EMT VIA A POSTTRANSCRIPTIONAL REGULON

4.1. Abstract
TGFβ

induces

epithelial-mesenchymal

transdifferentiation

(EMT)

accompanied by cellular differentiation and migration. EMT has emerged as a
fundamental

process

governing

embryonic

development,

adult

tissue

homeostasis and metastatic progression. Transcriptional array analyses have
failed to identity and validate ‘EMT signature genes’ because the transcriptome
does not mirror the proteome. We have previously shown that TGFβ posttranscriptionally regulates EMT by causing increased expression of two
transcripts required for EMT, Dab2 and ILEI, by modulating hnRNP E1
phosphorylation. Ectopic expression of ILEI and Dab2 do not render
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mesenchymal properties to cells in a TGFβ independent fashion suggesting
involvement of other mRNAs in the pathway. Using a genome-wide combinatorial
approach involving polysome profiling and RIP-Chip analyses using hnRNP E1,
we have identified a cohort of translationally regulated mRNAs required for
TGFβ-induced EMT. Coordinated translational regulation by hnRNP E1
constitutes a post-transcriptional regulon inhibiting the expression of related EMT
genes, thus enabling the cell to rapidly and coordinately suppress multiple EMT
genes and downregulate metastatic progression.
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4.2. Introduction
The epithelial-mesenchymal transition (EMT), in which cells undergo a
developmental switch from a polarized, epithelial phenotype to a highly motile
fibroblastic or mesenchymal phenotype, has emerged not only as a fundamental
process during normal embryonic development and in adult tissue homeostasis,
but is also essential for metastatic progression (Derynck et al., 2001; Zavadil et
al., 2005; Thiery et al., 2006). EMT is associated with changes in cell-cell
adhesion, remodeling of extracellular matrix, and enhanced migratory activity, all
properties that enable tumor cells to metastasize (Derynck et al., 2001; Zavadil et
al., 2005; Thiery et al., 2006). Numerous cytokines and autocrine growth factors,
including TGFβ, have been implicated in EMT (Bierie and Moses, 2006;
Massague, 2008). TGFβ exerts antiproliferative effects and functions as a tumor
suppressor during early stages of tumorigenesis, whereas at later stages it
functions as a tumor promoter aiding in metastatic progression (Bierie and
Moses, 2006; Massague, 2008).
We have earlier shown that regulation of gene expression at the posttranscriptional level plays an important role in TGFβ-mediated EMT. A transcriptselective translational regulatory pathway exists in which a ribonucleoprotein
(mRNP) complex, consisting of heterogeneous nuclear ribonucleoprotein E1
(hnRNP E1), binds to a 3’-UTR regulatory BAT (TGFβ activated translation)
element and silences translation of Dab2 and ILEI mRNAs involved in mediating
EMT. Ribonucleoprotein complexes (mRNPs) are diverse macromolecular
assemblies consisting of both protein and RNA components and possessing
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indispensable roles in the maturation of most RNAs and in the translation of
messenger RNAs (Varani et al., 1998; Cusack, 1999). We have shown that
TGFβ activates a kinase cascade terminating in the phosphorylation of hnRNP
E1 by isoform-specific stimulation of protein kinase Bβ/Akt2, inducing the release
of the mRNP complex from the 3’-UTR element, resulting in the reversal of
translational silencing and increased expression of Dab2 and ILEI transcripts and
subsequently mediates EMT.
Despite intensive transcriptional array analysis of human tumors, the
identity and validation of ‘EMT signature genes’ remains elusive (Pradet-Balade
et al., 2001; van’t Veer et al., 2002; Ramaswamy et al., 2003; Kang and
Massague, 2004; Vyas et al., 2009), partially because the transcriptome does not
mirror the proteome (van der Kelen et al., 2009). An alternative is expression
profiling on a genome wide scale, whereby non-translating and actively
translating pools of mRNAs are isolated by sucrose density gradient fractionation
and subsequently subjected to microarray analysis (Zong et al., 1999; Arava et
al., 2003; Bjorklid et al., 2003; Hofacker et al., 2003; Jechlinger et al., 2003; Vyas
et al., 2009). RNA-Binding Protein Immunoprecipitation-Microarray (Chip)
Profiling

is

an

advanced

high-throughput

analysis

of

mRNAs

that

coimmunoprecipitate with particular mRNA-binding proteins (Penalva et al.,
2004). An mRNA-binding protein of interest is immunoprecipitated, and the
associated mRNA is isolated and subsequently subjected to microarray analysis
(Johannes et al., 1999; Tenenbaum et al., 2000; Brown et al., 2001; Miyashiro et
al., 2003; Gerber et al., 2004; Inada and Guthrie, 2004; Penalva et al., 2004). A
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combinatorial approach involving expression profiling and RIP-chip analysis on a
genome-wide basis will yield definitive information on a particular regulatory
pathway.
shRNA-mediated silencing of Dab2 and ILEI in NMuMG cells is sufficient
to inhibit TGFβ-mediated EMT as analyzed morphologically and by loss of
upregulation of N-cadherin and vimentin, mesenchymal cell markers, whereas
their overexpression does not induce constitutive EMT, independent of TGFβ
signaling (Prunier and Howe, 2005). Thus Dab2 and ILEI are required, but not
sufficient, for TGFβ-induced EMT. Hence, we hypothesized that there are other
mRNAs which are being silenced by hnRNP E1 in a similar fashion, and which
cumulatively contributes to TGFβ-induced EMT. Hence, we adopted a
combinatorial approach involving polysome profiling and RIP-Chip analyses
using hnRNP E1 and filtered the array data based on the regulatory mechanism
of Dab2 and ILEI, i.e., enrichment in the polyribosome and loss of temporal
association with hnRNP E1 with 24 hs of TGFβ treatment. This led to the
identification of a cohort of four mRNAs that follow the same pattern of regulation
as Dab2 and ILEI and were further validated using qRT-PCR and immunoblot
analysis. Each of the identified target mRNA harbors a functional BAT element in
the 3’-UTR as revealed by functional testing using chimeric luciferase reporter
constructs and are required for TGFβ-induced EMT as evidenced by failure to
EMT in cells where these mRNAs are silenced. This cohort of mRNAs may
represent a new TGFβ responsive and hnRNP E1 mediated posttranscriptional
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regulon regulated directly at the posttranscriptional level in order to mediate
TGFβ-induced EMT in a temporal and expedited fashion.
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4.3. Materials & Methods
4.3.1. Cell culture and treatments
TGFβ2 was a generous gift from Genzyme Inc. and was used at a final
concentration of 5 ng/ml. NMuMG cells were cultured as described previously
(Prunier and Howe, 2005).
4.3.2. Plasmids construction
For construction of the chimeric luciferase constructs, luciferase cDNA
derived from pGL3-b vector was cloned into pcDNA3. A linker region containing
5’-EcoR1-Pac1-EcoRV-Nco-1-Xho-1-Xba-1

was

inserted

into

the

vector

downstream of the luciferase gene (pCMV-LL). Synthetic Dab2/BAT, ILEI/BAT,
Rhox5/BAT, Prl2c4/BAT, Ube3A/BAT and IL-11Rα2/BAT were generated with 5’EcoR1 and 3’-Xba-1 sites. pSilencer neo-shRNA-mouse Rhox5 and Ube3A were
constructed by annealing shRNA template oligonucleotides (target selected
through engine at Ambion and cloned into pSilencer neo vector (refer to Table S3
for oligonucleotide sequences). pSUPER-Dab2si construct has been generated
in the lab and described previously (Prunier and Howe, 2005). The ILEI siRNA, a
pool of 3 target-specific 19-25 nt. siRNAs were brought from Santa Cruz
Biotechnology Inc.
4.3.3. Preparation of cytosolic extract (S100 Fraction)
S100 fractions were prepared from unstimulated and TGFβ-treated
NMuMG cells as previously described (Mazumder and Fox, 1999) with minor
modifications. Briefly, the buffer used for cytosolic extraction contained 20 mM
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Hepes (pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM
DTT and protease inhibitor cocktail (Roche) (Hampton et al., 1998).
4.3.4. RNA immunoprecipitation
RNA immunoprecipitation was performed as described previously
(Penalva et al., 2004), the cytosolic extract was incubated with 10 µg of rabbit αhnRNP E1 antibody or rabbit α-IgG at 4°C overnight. 100 µL of protein ASepharose (Sigma) suspension (50% packed Sepharose in Buffer C) was added
and the incubation was continued overnight as described. The beads were
pelleted by 2 min centrifugation at 240 g at 4°C; the pellet was briefly washed
three times with 1 ml of IP Wash Solution (150 mM NaCl, 50 mM Tris pH 7.5,
0.5% NP40) and the Sepharose was transferred for elution into a fresh plastic
tube and pelleted again. The immunoprecipitated RNAs were isolated by Trizol
extraction as per manufacturer’s instructions. The isolated RNA was treated with
RNase-free DNase I to get rid of any contaminating DNA and used for the
Illumina MouseWG-6 v2.0 expression BeadChips.
4.3.5. Polysome profiling
Polysomes were analyzed from cytosolic fractions made in polysome lysis
buffer (10 mM HEPES, pH 7.5, 100 mM KCl, 2.5 mM MgCl2, 1 mM DTT, 50 U of
recombinant RNasin containing 100 µg/ml cycloheximide) as described
previously (Ray and Fox, 2007). Cytoplasmic extract was carefully layered over
10 to 50% (w/v) linear sucrose gradients and centrifuged at 1,50,000g for 4 hr.
Gradients were fractionated using a TELEDYNE ISCO gradient fractionation
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system equipped with a UA-6 detector following an upward displacement
method. Light RNP fractions, 40S, 60S, monosomes and heavy polysome
fractions were monitored by continuous UV absorption profiles at 264 nm, and 12
tubes of 1 ml fractions were collected. The fractions collected in the first four
tubes, representing light RNP and free ribosomes, were used to isolate a
translationally inactive pool of mRNAs, and fractions numbered five to ten,
representing polysomes, were used as a source of translationally active mRNAs.
Fractions 11 and 12 were discarded as heavy molecular weight aggregates.
Total RNA was isolated from these fractions by extraction with Trizol and purified
with RNeasy minikit, following the manufacturers’ protocols. The RNA was
quantitated and checked for purity by agarose formaldehyde gel and used for the
Illumina MouseWG-6 v2.0 expression BeadChips.
4.3.6. cDNA amplification and labeling
TotalPrep RNA amplification kit (Ambion, Foster City, CA, USA) was used
to generate biotin-16-UTP-labeled cRNA from 400 ng of total RNA. The
hybridization mix was prepared based on the guidelines provided in the Illumina
BeadStation 500X System Manual (Illumina, San Diego, CA, USA) using the
supplied reagents. Hybridization to the Illumina Mouse-6 expression BeadChip
was done for 16 h at 55°C on a BeadChip Hyb Wheel. The slide was washed for
15 min on an orbital shaker at RT in a staining dish with 250 ml of E1BC wash
solution, followed by incubation in 100% ethanol for 10 min at RT, and washed
again in E1BC for 2 min. For the blocking reaction the slide was placed in a
BeadChipWash Tray containing 4ml of Block E1 buffer on a rocker mixer for 10
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min. Staining was performed for 10 min in a tray with 2 ml of buffer E1 and 1
µg/ml Cy3-streptavidin (Amersham Biosciences, Piscataway, NJ, USA), followed
by incubation in E1BC for 5 min. The slide was dried by centrifugation (275 rpm,
5 min) and kept in the dark until ready to scan. Scanning used the Illumina
BeadArray Reader software together with the Illumina BeadStation 500 platform
and was read by the Illumina BeadXpressTM Reader.
4.3.7. Data Analysis
Illumina data were analyzed by using the Illumina BeadStation 1.5.1.3.
Software. After clustering, results were screened. The data were subtracted for
background and normalized using the rank invariant option. A RefSeq gene was
accepted as expressed if the detection value was ≥0.99. The ratios of the raw
signal intensity values of the mRNAs in the different test groups of the selected
genes were subsequently determined.
4.3.8. Isolation of total RNA and RT-PCR
Isolation of total RNA and RT-PCR was done as described previously
(Wildey et al., 2003). Refer to Table II for primer sequences.
4.3.9. Quantitative Real Time PCR Analysis
qRT-PCR was done as described previously (Vyas et al., 2009). Please
refer to Table II for primers used. The results were expressed after normalization
to β-Actin expression levels from three different experiments. Data has been
represented as means ± S.D.
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4.3.10. Preparation of cell lysates and immunoblot analysis
For immunoprecipitation and immunoblot analysis, cells were lysed in
buffer D and immunoprecipitation carried out as previously described (Hocevar et
al., 1999).
4.3.11. Prediction of putative BAT elements in the potential target mRNAs
3'-UTR sequence of the target mRNAs were examined for structural
similarities with Dab2/BAT and ILEI/BAT elements using Foldalign program
(http://foldalign.ku.dk/), which allowed clustering of RNA sequences independent
of sequence homology (Vyas et al., 2009). Various lengths of identified
sequences were expanded to 33 nucleotides randomly and folded using the
Mfold algorithm (Zuker, 2003). Structures that resembled the Dab2/BAT were
chosen by visual selection and were screened for structure-based homology with
the Dab2 and ILEI BAT elements using the Foldalign program, version 2.0.3
(Vyas et al., 2009). Statistical relevance of predicted structure existence was
predicted by Sfold algorithm (Ding and Lawrence, 1999). Finally, structures were
evaluated with UNAFold algorithm to check for hybridization characteristics and
melting pathways to confirm uniform predictive function (Markham and Zuker,
2005).
4.3.12. In vitro luciferase assay
In vitro luciferase assay was performed as previously described
(Mazumder and Fox, 1999).
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4.3.13. RNA pull-down
WT and mutant BAT synthetic RNA (cRNA) was bound to cyanogen
bromide-activated sepharose beads. RiboMax kit was used to generate
milligrams quantity of synthetic 33nt RNA from the template DNA. For RNA pull
down experiments, different amount (0.5 mg) of cytosolic extracts prepared from
unstimulated and TGFβ treated NMuMG cells were incubated at 4 0C for 2 hr
with the cRNA beads. Following the incubation period the beads are washed with
0.3 M sodium chloride and resolved by 10% SDS-PAGE.
4.3.14. Statistical analysis
Data obtained from qRT-PCR are presented as mean ± s.d., n=3.
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Table II. Primers and oligonucleotide sequences for constructs used.
Primer/oligonucleotide sequence (5’→
→3’)

Name
IL-11Rα
α2 shRNA 5’-UTR

GATCCATCCGGGTAGGTATTAGAGTTCAAGAGACTCTAATACCTACCCGGATTTTTTTGGAAA

Top
IL-11Rα
α2 shRNA 5’-UTR

AGCTTTTCCAAAAAAATCCGGGTAGGTATTAGAGTCTCTTGAACTCTAATACCTACCCGGATG

Bottom
Prl2c4 shRNA 5’-UTR Top

GATCCGTAGCTCTCAGAAATATAATTCAAGAGATTATATTTCTGAGAGCTACTTTTTTGGAAA

Prl2c4 shRNA 5’-UTR

AGCTTTTCCAAAAAAGTAGCTCTCAGAAATATAATCTCTTGAATTATATTTCTGAGAGCTACG

Bottom
Rhox5 shRNA 5’-UTR Top

GATCCGCATACTTTGGAGAGAGAAGTTCAAGAGACTTCTCTCTCCAAAGTATGGCTTTTTTGGAAA

Rhox5 shRNA 5’-UTR

AGCTTTTCCAAAAAAGCCATACTTTGGAGAGAGAAGTCTCTTGAACTTCTCTCTCCAAAGTATGCG

Bottom
Ube3A shRNA 5’-UTR Top

GATCCGATGGCACATTATTTAGTCTTCAAGAGAGACTAAATAATGTGCCATCTTTTTTGGAAA

Ube3A shRNA 5’-UTR

AGCTTTTCCAAAAAAGATGGCACATTATTTAGTCTCTCTTGAAGACTAAATAATGTGCCATCG

Bottom
mDab2-Exon9-F1

AAGCAGGACTTGGAAAGTTCTGT

mDab2-R2

CATTGCCTTTGAAGAGATCCAGAA

mILEI- F1

AAATGAGGGTAGCAGGAGCT

mILEI-R1

AACATTGTCCTCCAGGCAG

mIL-11Rα
α2-F1

ACTCAGTCCAGACCCCTTCCC

mIL-11Rα
α2-R1

GGAGACATCTGTCCTCAAAGG

mPrl2c4- F1

CTTCAGAATGGAGATGAAGAAAAGA

mPrl2c4-R1

TAAAAAGTAGCTCTCAGAAATAT

mRhox5-F1

GCCTGGGAGTCAAGGAA

mRhox5-R1

CATAGGACCAGGAGCACCA

mUbe3A-F1

ATATTCCGGAAGTAAAAGGACATTA

mUbe3A-R1

AACAGGCACAGACAGAGCAC

mβ−
β−Actin-Exon4-F1
β−

AGCTGTGCTATGTTGCTCTAGACTT

mβ−
β−Actin-Exon5-R1
β−

CACTTCATGATGGAATTGAATGTAG
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4.4. Results
4.4.1. Experimental design to identify potential target mRNAs that are
translationally upregulated by TGFβ and differentially regulated by hnRNP E1 in a
TGFβ-dependent manner
We have previously shown in Chapter II that NMuMG cells undergo EMT
following TGFβ stimulation for 24 hs. Hence, for the expression profiling we isolated
non-translating, non-polysomal (40S, 60S, and monosomes) and actively translating
polysomal fractions from cells treated ± TGFβ for 24 hs by sucrose gradient
centrifugation (Fig. 4.1A). We have earlier shown in Chapter II that hnRNP E1 binds the
BAT elements of Dab2 and ILEI and inhibits their translation in control cells and TGFβ
treatment leads to loss of temporal association with hnRNP E1 and subsequent
translational activation of the two

mRNAs. For the RIP-Chip profiling, we

immunoprecipitated cytosolic extracts made from NMuMG cells treated ± TGFβ for 24
hs with anti-hnRNP E1 antibody and IgG (Fig. 4.1A). The protocol was repeated for
cytosolic extracts made from E23 cells, NMuMG cells stably overexpressing hnRNP E1,
which were previously shown to be refractory to TGFβ-induced EMT in Chapter III. The
rationale behind using the E23 cells for the RIP-Chip analysis was to use it as an
external control for normalization of the microarray data obtained from NMuMG cells
(mRNAs in which TGFβ treatment leads to loss of temporal association with hnRNP E1
in NMuMG cells will still be associated with hnRNP E1 in the E23 cells). mRNA was
isolated from the different fractions and the immunoprecipitates. Total, unfractionated
RNA was also obtained from NMuMG cells treated ± TGFβ for 24 hs. The different
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pools of mRNAs were subjected to cDNA synthesis and amplification before being
subjected to microarray analysis using the Illumina MouseWG-6 v2.0 Chip.
4.4.2. Identification of the ‘EMT signature genes’ panel
The data obtained from the microarray was subjected to statistical analysis and
normalization by the Illumina BeadStudio software. Cut-off intensity for significant
detection for polysome profiling was fixed at 5.0 folds [(P/NP)24h/(P/NP)0h]. For RIPChip, the cutoff was fixed at < 1.0 fold (IP0h/IP24h). As depicted in Fig. 4.1B, the data
revealed 83 genes that are translationally upregulated following TGFβ stimulation and
23 genes that selectively interact with hnRNP E1 under unstimulated conditions and
subsequently lose their temporal association following TGFβ addition. A complete list of
the different target mRNAs identified by the expression profiling and RIP-Chip is
presented in Tables III and IV, respectively. Self-organizing maps (SOM) clustering
analysis and dendogram (Fig. 4.2A) confirms that the obtained data conforms to
external controls and normalization platforms adopted for data analysis. As an example,
total mRNA isolated from unstimulated and TGFβ-treated cells (S5 and S6, respectively
in Fig. 4.2A), grouped closely as is normally expected, whereas mRNAs from nonpolysomal and polysomal pools (S3 and S4, respectively in Fig. 4.2A) from TGFβ
treated cells mapped to distant loci in the dendogram.
The EMT signature genes were obtained by intersecting the data obtained from
polysome profiling and RIP-Chip analyses and identified 5 target mRNAs (Fig. 4.2B).
Both approaches identified ILEI mRNA, thus confirming that the experimental approach
adopted was valid. The other target genes that were identified were interleukin-11
receptor alpha, chain 2 (IL-11Rα2), reproductive homeobox 5 (Rhox5), prolactin family
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2, subfamily c, member 4 (Prl2c4) and ubiquitin protein ligase E3A (Ube3A). But we did
not identify Dab2 mRNA. This can be either due to the high (>5.0) cut-off limit of
detection that we used for the analysis or because of inefficient hybridization between
the samples and the Dab2 probes on the array. The ratios of the raw signal intensity for
all the samples that were subjected to microarray analysis for each of the five potential
target mRNAs are represented as heat maps and bar diagrams (Fig. 4.3A, B). As
depicted, the color progression scale distinctively shows that even though the pattern of
regulation for the five potential targets is same, the fold induction levels are different.
4.4.3. Validation of potential target mRNAs
The presence of ILEI, Rhox5, Ube3A, IL-11Rα2 and Prl2c4 mRNAs in each
sample subjected to microarray analysis was determined by semi-quantitative RT-PCR
analysis (Fig. 4.4). Presence of Dab2 was also determined in the samples. The
expression of all the potential targets corroborated with the microarray data analysis.
Similar results were obtained for Dab2, even though it was not detected in the
microarray analysis. For each target, message was found to translocate to the actively
translating polysome fractions with TGFβ treatment, while they were found sequestered
to the non-translating pools in the unstimulated cells. The targets also showed
differential temporal association with hnRNP E1 in unstimulated and TGFβ treated
NMuMG cells, but not in E23 cells. We further validated the targets by monitoring their
steady state mRNA and protein expression levels. Total mRNAs were isolated from
NMuMG cells treated with TGFβ for the indicated times and subjected to quantitative
Real Time PCR (qRT-PCR) to assess steady state mRNA expression levels of the
target genes (Fig. 4.5). As shown, none of the mRNAs showed >2.5 fold induction in the
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transcript expression levels. But TGFβ treatment of NMuMG cells led to increased
expression levels of protein for all the potential targets (Fig. 4.6). Taken together, the
results suggest that each of the identified target mRNAs is translationally upregulated
by TGFβ and further validates the identified targets.
4.4.4. In silico analysis of the 3’-UTRs of potential target mRNAs for translational
silencing
A 33nt BAT element mediating TGFβ-induced translational regulation of Dab2
and ILEI has been previously defined in Chapter II. As shown in Fig. 4.5A, the BAT
element consists of a stem-loop structure with an asymmetric bulge and similarity in
Dab2/BAT and ILEI/BAT is based on secondary structure and not sequence information
contained within the structure. It was imperative to determine whether the Ube3A,
Prl2c4, Rhox5 and IL-11Rα2 also contain the BAT element in their 3’-UTRs. Putative
BAT elements in the target mRNAs were predicted using structure information
contained within the BAT element as detailed in Materials & Methods. Putative BAT
elements were identified in Rhox5 (nt 27-60) (UTRdb ID: 3MMU062400), Prl2c4 (nt 2254) (UTRdb ID: 3MMU060233), Ube3A (nt 1098-1130) (UTRdb ID: 3HSA011848) and
IL-11Rα2 (nt 153-183) (UTRdb ID: 3MMU026940). The resultant structures appeared to
contain significant folding similarity as identified by the stem-loop and asymmetric bulge
(Fig. 4.7).

It should be noted that Ube3A was not detected in the mouse 3’-UTR

database and hence the corresponding human sequence was used to predict putative
BAT element.
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4.4.5. The predicted BAT elements in the target mRNAs interacts with hnRNP
E1 in vitro and can functionally repress translation
Temporal association of hnRNP E1 with the predicted BAT elements in
the target mRNAs was investigated using a RNA pull-down from cytosolic
extracts from unstimulated and TGFβ-treated NMuMG cells (Fig. 4.8). The data
demonstrate that the predicted 33nt elements could precipitate hnRNP E1 from
unstimulated extracts but that TGFβ induced the loss of binding of hnRNP E1 to
the RNA. hnRNP E1 could not bind the U10A or the bulge mutants suggesting
the indispensability of the stem-loop and the asymmetric bulge for functional
specificity. We next investigated if the predicted elements can functionally
repress translation of chimeric luciferase transcripts, where the predicted BAT
elements were cloned downstream of a luciferase (Luc) reporter gene.
Unstimulated cytosolic extracts inhibited the translation of all the chimeric
luciferase constructs tested (Fig. 4.9). In vitro translation repression of LucDab2/BAT and Luc-ILEI/BAT was relieved after 3 hr of TGFβ stimulation and
similar results obtained for the chimeric constructs for Rhox5, Prl2c4, Ube3A and
IL-11Rα2 (Fig. 4.9). Together, the results show that the predicted structures
bearing secondary structure similar to Dab2/BAT and ILEI/BAT elements are
effective for translational silencing and reversion of translational silencing is seen
following 3 hs of TGFβ treatment.
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4.4.6. Modulation of hnRNP E1 expression or its posttranslational
modification in NMuMG cells alters expression of the identified targets
We have previously generated NMuMG cells either stably overexpressing
hnRNP E1 (E23 cells) or silenced hnRNP E1 expression (SH14 cells). We had
also knocked in either WT (KIWT6 cells) or a phospho-mutant (Ser43Ala) (KIM2
cells) version of hnRNP E1 into SH14 cells (Chapter III). SH14 cells constitutively
EMT even in the absence of TGFβ, E23 cells was refractory to TGFβ-induced
EMT. Knock-in of either the WT or Ser43Ala mutant hnRNP E1 rescued the
epithelial phenotype and TGFβ stimulation caused EMT in KIWT6, but blocked it
in KIM2 cells (Chapter III).
We hypothesized that if the identified targets are true modulators of TGFβinduced EMT like Dab2 and ILEI, their expression levels should mimic the later in
the NMuMG, E23, SH14, KIWT6 and KIM2 cells. Whole cell lysates were
prepared from these cells following TGFβ stimulation for the indicated times and
then probed with the respective antibodies. As shown in Fig. 4.10, in NMuMG
and KIWT6 cells, TGFβ induced the protein expression levels in a time
dependent fashion, whereas in E23 and KIM2 cells, none of the target mRNAs
were being expressed even after TGFβ treatment. Correspondingly, constitutive
expression of the target mRNAs were detected in the SH14 cells. Overall, the
target mRNAs were being expressed in a fashion similar to Dab2 and ILEI and
was suggestive of an equivalent role in TGFβ-induced EMT.
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We postulated that if the target mRNAs are required for EMT, then
silencing the expression of even one of the mRNAs will rescue epithelial cell
properties in the SH14 cells. sh-RNA mediated silencing of either Rhox5 or
Ube3A attenuated induction of EMT as evident by loss of expression of
mesenchymal cell markers, N-cadherin and vimentin (Fig. 4.11) and loss of
morphological features associated with mesenchymal cells (data not shown)
Cumulatively, these results clearly support our results that the role of hnRNP E1
on EMT is mediated through induction of a cohort of six mRNAs and that they are
each critical mediator of EMT.
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Figure 4.1: Schematic representation of experimental design for combinatorial
polysome profiling and RIP-Chip analyses.
(A) For expression profiling, cell lysates from untreated and TGFβ-treated (24 hs)
NMuMG cells were fractionated by sucrose gradient (10-50%) centrifugation and RNA
was isolated from the non-translating and actively translating pool, designated as NP
and P, respectively. For the RIP-Chip analysis, cytosolic extracts made from untreated
and TGFβ-treated (24 hs) NMuMG and E23 cells were immunoprecipitated with αhnRNP E1 antibody or an isotype control and RNA was isolated from the
immunoprecipitates. Following cDNA synthesis and amplification step, the cDNA was
hybridized to Illumina Mouse WG-6 v2.0 chip (with capacity for 6 samples) and analyzed
by Illumina BeadXpressTM Reader. Data obtained was analyzed by Illumina BeadStudio
Software. (B) Flow chart representing the scheme followed for data filtering and
normalization to arrive at the ‘EMT signature genes’ (annotates as translationally
upregulated by TGFβ and differentially regulated by hnRNP E1 in a TGFβ-dependent
manner). X and Y represent translationally upregulated and hnRNP E1 differentially
regulated genes, respectively.
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Figure 4.2: Combinatorial polysome profiling and RIP-Chip identifies an EMT
signature profile.
(A) Raw expression data were exported from Illumina BeadXpressTM Reader and
subjected to self-organizing maps (SOM) clustering analysis to confirm rigorousity of
data obtained with respect to external controls and normalization platforms adopted for
data analysis. S1 through S12 represent the sample identifications used for the array
analysis and definition of each has been included.
(B) Venn diagram summarizing the results of the genome wide analysis performed.
Identity of the 5 genes translationally upregulated by TGFβ and differentially regulated
by hnRNP E1 in a TGFβ-dependent manner has been included.
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Figure 4.3: Quantitative representation of data analysis as obtained from Illumina
BeadStudio Software.
(A) Heat map generated from the Illumina Mouse WG-6 v2.0 chip analysis of the genes
translationally upregulated by TGFβ and differentially regulated by hnRNP E1 in a
TGFβ-dependent manner. The color progression scales represent the relationship
between different colors and relative quantities of the particular mRNA.
(B) Bar diagram representing the raw intensity profiles obtained for each sample in the
Illumina analysis.

131

Figure 4.4: Validation of the potential target mRNAs.
Semi-quantitative RT-PCR analysis using gene specific primers for the potential targets
and β-Actin (control) on the samples that were subjected to illumina analysis.
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Figure 4.5: The identified targets are not significantly induced transcriptionally by
TGFβ.
Total mRNAs were isolated from NMuMG cells treated with TGFβ for the indicated times
and subjected to quantitative Real Time PCR (qRT-PCR) to assess steady state mRNA
expression levels of the potential target genes. qRT-PCR was carried out using SYBR
Green PCR Master Mix and ABI Thermo Cycler. The value depicted is representative of
relative amount of test mRNA normalized to β-Actin from three different experiments.
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Figure 4.6: Expression of all the identified target transcripts are induced by TGFβ.
Immunoblot (IB) analysis examining protein expression levels of the potential targets in
NMuMG cells treated with TGFβ for the indicated times. One of the blots was stripped
and re-probed for β-Actin as a loading control.
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Figure 4.7: The 3’-UTR of the identified mRNAs contain the BAT element.
Secondary structures of the target mRNAs with similarities to Dab2/BAT element.
Specific regions of the 3’-UTR were selected and the structures were generated as
described in Materials & Methods (dGDab2/BAT = -5.0 Kcal/mol; dGILEI/BAT = -2.5 Kcal/mol;
dGRhox5/BAT = -0.10 Kcal/mol; dGPrl2c4/BAT = -4.7 Kcal/mol; dGUbe3A/BAT = -1.9 Kcal/mol; dGIL11R2/BAT = -10.4 Kcal/mol). ILEI/BAT element was folded under constraints (F 5 0 2)/ (F 9
0 2)/ (P 11 0 2) and Prl2c4/BAT element was folded under (F 2 0 1)/ (F 29 0 1)
constraints.
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Figure 4.8: The BAT elements in the target mRNAs temporally associates with
hnRNP E1.
RNA affinity pull-down and IB analyses using S100 cytosolic extracts for the times
indicated to define the temporal association of hnRNP E1 with the different BAT
elements. Neck (U10A) and bulge (lacking asymmetric bulge) mutants represent BAT
element forms that loose the secondary structure.
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Figure 4.9: The BAT elements in the target mRNAs can functionally repress
translation.
IVT analyses with chimeric luciferase constructs of the BAT element present in Dab2
and the identified targets show that TGFβ treatment relieves translational silencing
conferred by the WT following 3 hr of TGFβ treatment.

137

Figure 4.10: Modulation of hnRNP E1 expression or its posttranslational
modification alters expression of the identified targets.
IB analysis monitoring Dab2, ILEI, Rhox5, Prl2c4. Ube3A, IL-11Rα2 and Hsp90 protein
levels in WT, E23, SH14, KIWT6 and KIM2 cells treated with TGFβ for the times
indicated.
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Figure 4.11: Role of hnRNP E1 on EMT is mediated by the identified transcripts.
IB analysis of WCLs derived from SH14 cells, un-transfected or transiently transfected
with ILEI and Dab2 siRNA and Rhox5 and Ube3A shRNA to confirm knockdown of
targets. IB analysis examining N-cadherin protein levels in these transfected cells to
confirm rescue of epithelial phenotype in the SH14 cells (fifth panel).
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Table III The list of the potential target mRNAs showing significant increase in translational competence in
NMuMG cells following TGFβ stimulation for 24 hours. The ratios of polysomal vs. non-polysomal
abundance of mRNAs before and after TGFβ treatment were measured by analyzing the raw signal intensity
data using the Illumina BeadStation software. mRNAs presented in this Table show a significant induction
(>5 folds) in translational potency. The data was normalized to fold induction of total mRNA.

Symbol

Definition

NCBI
Accession

Fold Induction of
Total mRNA
=(mRNA24hs/
mRNA0 hs)

Fold Induction of
Polysomal mRNA
= (Polysome/Nonpolysome)24hs/
(Polysome/Nonpolysome)0 hs

NM_053115.1

1.04

7.31

Acta2

Acyl-coenzyme A oxidase 2,
branched chain
Actin, alpha 2, smooth muscle. Aorta

NM_007392.2

0.98

6.77

Adssl1

Adenylosuccinate synthetase like1

NM_007421.1

0.87

15.24

Ak1

Adenylate kinase 1

NM_021515.2

0.93

7.88

Apoc2

Apolipoprotein C-II

NM_009695.2

0.77

9.87

Arf5

ADP-ribosylation factor

NM_007480.1

0.63

5.82

Arl1

ADP-ribosylation factor-like 1

NM_025859.1

1.02

5.02

Arpc5

Actin related protein 2/3 complex

NM_026369.1

0.73

5.80

B2m

Beta-2 microglobulin

NM_009735.3

0.79

8.96

Bace1

Beta-site App cleaving enzyme 1

NM_011792.4

0.79

5.62

Bzw2

NM_025840.2

0.98

5.09

NM_025451.1

1.15

5.10

Casp6

Basic leucine zipper and W2 domains
2
Calcium/calmodulin-dependent
protein kinase II inhibitor 1
Caspase 6

NM_009811.2

0.94

7.44

Cbfb

Core binding factor beta

NM_022309.3

1.07

5.14

Ccdc124

Coiled-coil domain containing 124

NM_026964.3

1.03

5.17

Ccl2

Chemokine (C-C motif) ligand 2

NM_011333.3

0.70

10.44

Cd9

CD9 antigen

NM_007657.3

0.68

6.60

Cdh6

Cadherin 6

NM_007666.3

0.78

6.76

Cdkn2b

Cyclin-dependent kinase inhibitor
2B(p15, inhibits CDK4)

NM_007670.3

1.03

6.88

Centd3

Centaurin, delta 3

NM_139206.1

0.88

6.92

Cfi

Complement component factor i

NM_007686.2

0.77

15.17

Chmp2a

Chromatin modifying protein 2A

NM_026885.2

0.81

9.16

Chrna1

Cholinergic receptor, nicotinic, alpha
polypeptide 1

NM_007389.4

0.96

7.57

Chst8

Carbohydrate (N-acetylgalactosamine
4-0) sulfotransferase 8

NM_175140.3

0.84

8.88

Acox2

Camk2n1
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Ctsw

Cathepsin W

NM_009985.3

1.09

5.24

Cited2

Cbp/p300-interacting transactivator,
with Glu/Asp-rich carboxy-terminal
domain, 2

NM_010828.2

1.05

12.84

D6Wsu176e/ILEI

Wayne State University 176,
expressed

NM_138587.4

0.84

6.43

Ddit4

DNA-damage-inducible transcript 4

NM_029083.2

0.80

5.88

Efna1

Ephrin A1

NM_010107.3

0.88

7.76

Eif5

Eukaryotic translation initiation factor
5

NM_178041.1

1.04

8.05

Elf2

E74-like factor 2

NM_023502.1

0.69

6.09

Epb4.1l4b

erythrocyte protein band 4.1-like 4b

XM_001476174.1

1.11

5.04

Fcrl1

Fc receptor-like 1

NM_178165.3

0.99

6.18

Fxyd5

FXYD domain-containing ion
transport regulator 5

NM_008761.2

0.76

8.76

Gadd45a

Growth arrest and DNA-damageinducible 45 alpha

NM_007836.1

0.92

32.08

Ghr

Growth hormone receptor

NM_010284.2

0.84

5.14

Gpd1

Glycerol-3-phosphate dehydrogenase
1 (soluble)

NM_010271.2

0.85

6.31

H2-Ke2

H2-K region expressed gene 2

NM_010385.2

0.96

5.58

H60

Histocompatibility 60

NM_010400.2

0.76

5.22

Hn1

Hematological and neurological
expressed sequence 1

NM_008258.1

1.07

5.78

Hspb8

Heat shock protein 8

NM_030704.1

0.81

6.23

Ifitm2

Interferon induced transmembrane
protein 2

NM_030694.1

0.85

5.52

IL11

Interleukin 11

NM_008350.2

0.86

68.52

IL11Rα1

Interleukin 11 receptor, alpha chain

NM_010549.2

0.83

6.36

Itgb5

Integrin beta 5

NM_010580.1

0.85

7.87

Klf13

Kruppel-like factor 13

NM_021366.2

0.97

7.39

Krt23

Keratin 23

NM_033373.1

0.97

5.80

Lbp

Lipopolysaccharide binding protein

NM_008489.2

0.77

26.43

Lce1f

Late cornified envelope 1F

NM_026394.2

0.81

12.42

Lmcd1

LIM and cysteine-rich domains 1

NM_144799.1

0.99

6.71

Lrp11

Low density lipoprotein receptorrelated protein 11

NM_172784.2

0.73

15.91

Map2k2

Mitogen activated protein kinase
kinase 2

NM_023138.3

0.99

9.74

Mfsd1

Major facilitator superfamily domain
containing 1

NM_025813.3

0.74

5.72
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Mxd4

Max dimerization protein 4

NM_010753.2

0.83

6.09

Notch4

Notch gene homolog 4

NM_010929.2

0.95

11.98

Nppb

Natriuretic peptide precursor type B

NM_008726.3

0.85

11.19

Ostf1

Osteoclast stimulating factor 1

NM_017375.2

0.90

5.84

Pdgfb

Platelet derived growth factor, B
polypeptide

NM_011057.3

1.25

5.29

Pik3ap1

Phosphoinositide-3-kinase adaptor
protein 1

NM_031376.2

1.20

6.44

Prl2c4

Prolactin family 2, subfamily c,
member 4

NM_011954.2

0.73

5.63

Psmd7

Proteasome (prosome, macropain)
26S subunit, non-ATPase, 7

NM_010817.1

0.80

5.18

Rdh10

Retinol dehydrogenase 10

NM_133832.3

0.78

5.68

Rhoc

Ras homolog gene family, member C

NM_007484.1

0.71

6.96

Rhox5

Reproductive homeobox 5

NM_008818.2

0.90

384.57

Rsrc1

Arginine/serine-rich coiled-coil 1

NM_025822.3

1.17

7.04

Sdc3

Syndecan 3

NM_011520.3

0.84

9.89

Sh3bp2

SH3-domain binding protein 2

NM_011893.2

1.07

5.05

Slc25a45

Solute carrier family 25, member 45

NM_134154.3

1.13

5.41

Sox4

SRY-box containing gene 4

NM_009238.2

1.13

5.27

Tcf4

Transcription factor 4

NM_013685.2

0.92

5.42

Tgfbr1

Transforming growth factor, beta
receptor I

NM_009370.2

0.86

9.10

Tnnt2

Troponin T2

NM_011619.1

1.17

5.04

Twist2

Twist homolog 2

NM_007855.2

0.89

13.20

Ube3A

Ubiquitin protein ligase E3A

NM_011668.2

0.98

7.29

Ubtd1

Ubiquitin domain containing 1

NM_145500.3

0.78

5.58

Vegfc

Vascular endothelial growth factor C

NM_009506.2

0.73

10.14

Vti1a

Vesicle transport through interaction
with t-SNAREs homolog 1A

NM_016862.3

0.93

5.58

Wbp5

WW domain binding protein 5

NM_011712.2

1.07

7.20

Wnt7b

Wingless-related MMTV integration
site 7B

NM_009528.2

0.92

7.73

Ypel5

Yippee-like 5

NM_027166.5

0.97

5.25
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Table IV. The list of the potential target mRNAs showing significant decrease in temporal association with
hnRNP E1 in NMuMG cells following TGFβ stimulation for 24 hours. The ratios of abundance of mRNAs
before and after TGFβ treatment were measured by analyzing the raw signal intensity data using the
Illumina BeadStation software. mRNAs presented in this Table show a significant induction (>5 folds) in
hnRNP E1 association in control cells and ≤1 fold in TGFβ treated cells. The data was normalized to fold
induction in E23 cells and for IP: IgG in NMuMG cells.
Symbol

Definition

NCBI Accession

Fold Induction of
hnRNP E1 association
in NMuMG cells
= (IP-E1 0h/IP-E1 24h)

1700116B05Rik

XM_354966.1

22.06592

9630013A09Rik

AK035873

5.004426

Aldehyde dehydrogenase family
6, subfamily A1
Cdc42 GTPase-activating protein
(Cdgap)
CDKN2A interacting protein

NM_134042.2

35.77283

NM_020260.2

77.86498

NM_172407.2

20.64178

Wayne State University 176,
expressed

NM_138587.4

5.432151

AK007931

7.392065

Aldh6a1
Cdgap
Cdkn2aip
D6Wsu176e/ILEI
Ela1
Fbln5

Fibulin 5

NM_011812.3

8.065797

Fkhl18

Forkhead-like 18

NM_010226.2

24.42089

Gdi2

Guanosine diphosphate (GDP)
dissociation inhibitor 2
Prdeicted gene model 920,
(NCBI)

NM_008112.4

182.9481

XM_001003788.1

7.051355

AK017246

21.81118

Gm920

Gt(ROSA)26asSor
Igfl3

IGF-like family member 3

NM_001003393.1

24.00653

Krtap13

Keratin associated protein 13

NM_010671.1

5.941195

LOC100038993

Interleukin 11 receptor, alpha
chain 2

NM_001100596.1

5.588266

AK036415

72.07244

Mpp1
Npbwr1

Neuropeptides B/W receptor 1

XM_912251.2

9.240859

Prl2c4

Prolactin family 2, subfamily c,
member 4

NM_011954.2

6.477277

Rhox5

Reproductive homeobox 5

NM_008818.2

721.8162

Slc16a11

NM_153081.2

6.416259

Tessp2

Solute carrier family 16
(monocarboxylic acid
transporters)
Testis serine protease 2

NM_153099.1

79.68688

Trp73

Transformation related protein 73

NM_011642.2

5.178366

Ube3a

Ubiquitin protein ligase E3A

NM_001033962.1

6.298723

Xpo4

Exportin 4

NM_020506.1
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7.194109

4.5. Discussion
We have identified a cohort of translationally regulated mRNAs required
for TGFβ-induced EMT by using a combinatorial approach involving polysome
profiling and RIP-Chip analysis using hnRNP E1 as the bait.

Rigorous data

analyses have identified the targets, which have been further validated using a
combination of molecular and functional approaches. mRNA translation state
change was considered significant only if the following two criteria were met: (a)
the signal intensity of the non-translated RNA filter of resting cells and the
translated RNA filter of activated cells exceeded the medial signal intensity of all
the array elements, and (b) the value of the change in translation state was >5.0fold of median value of the change of mRNA distribution of all the genes on the
arrays. Similarly, for the RIP-Chip analysis, the ratios of raw signal intensities
were normalized to the mean signal level, internal standards (housekeeping
genes), and to the levels of external standards (E23 cells and IgG isotype
control). The validity of the predicted targets are further ascertained by the facts
that (a) our approach identified ILEI proving the validity of the approach; (b)
presence of functional BAT elements, resembling a pattern similar to Dab2 and
ILEI BAT elements, in the 3’-UTRs of the identified target mRNAs; and (c)
indispensability of the target in TGFβ-induced EMT as evidenced by failure to
EMT post shRNA-mediated silencing of Rhox5 and Ube3A in the SH14 cells.
Protein expression levels depend on the rate of transcription, as well as
other defined control mechanisms, such as mRNA stability (Garcia-Martinez et
al., 2004), nuclear export and mRNA localization (Hieronymus and Silver, 2004),
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translational regulation (Beilharz and Preiss, 2004), and finally protein
degradation (Beyer et al., 2004). Post-transcriptional regulation is mainly
controlled by the binding of RBPs to regulatory regions in the UTRs of mRNAs.
An advantage of genome-wide approaches, like the one adapted for the current
study, is their unbiased nature and rigorous testing, which enables the discovery
of unexpected connections.
Prediction of putative BAT elements in the identified target mRNAs was
based on structure-based homology. Validation of the BAT elements was
performed by a functional loss-of-silencing assay using chimeric luciferase
reporter transcripts. All the putative BAT elements in Fig. 4.5A have a stem-loop
structure with an asymmetric bulge; however, the structures show considerable
diversity, which can be attributed to the somewhat arbitrary nature of RNA
structure prediction itself (Vyas et al., 2009).
The BAT element in the 3’-UTR of Dab2, ILEI and the identified transcripts
provides further insights into the importance of regulatory elements in
maintenance of homeostasis. Coordinated translational regulation by hnRNP E1
constitutes a post-transcriptional regulon inhibiting the expression of related EMT
genes (Keene and Tenenbaum, 2002). Eukaryotic regulons are defined as
higher-order genetic units (quasi genome) consisting of monocistronic mRNA
subsets under the control of a regulatory RNA binding protein (Keene and Lager,
2005). RNA binding proteins have been shown to specifically bind transcripts
encoding functional and colocalized protein classes (Brown et al., 2001;
Miyashiro et al., 2003; Waggoner and Liebhaber, 2003; Gerber et al., 2004).
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Post-transcriptional operons or regulons may have evolved as mechanisms to
rapidly and coordinately suppress multiple EMT genes and downregulate
metastatic progression.
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CHAPTER V
SUMMARY AND PERSPECTIVE

We have identified a transcript-selective translational regulation pathway
by which TGFβ modulates expression of mRNAs required for EMT, and EMT
itself in vitro and tumorigenesis and metastasis in vivo. hnRNP E1 binds to a
structural, 33-nucleotide TGFbeta-activated translation (BAT) element in the 3’UTR of a cohort of mRNAs (Dab2, ILEI, Rhox5, Ube3A, IL-11Rα2 and Prl2c4),
thereby repressing their translation. TGFβ activates a kinase cascade terminating
in phosphorylation of Ser43 of hnRNP E1, by isoform-specific stimulation of
protein kinase Bβ/Akt2, inducing its release from the BAT element and loss of
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translational silencing of the target mRNAs. Modulation of hnRNP E1 expression,
or of its Ser43 site, alters TGFβ-mediated loss of translational silencing and EMT.
The BAT element in the 3’-UTR of these transcripts provides further
insights into the importance of regulatory elements in maintenance of
homeostasis.

Coordinated

translational

regulation

constitutes

a

post-

transcriptional regulon inhibiting the expression of related EMT genes. Posttranscriptional regulons may have evolved as mechanisms to rapidly and
coordinately suppress multiple EMT genes and downregulate metastatic
progression. The autocrine response of cells to TGFβ-induced Akt2 activation,
and subsequent translational activation of transcripts involved in EMT, may
represent a mechanism by which increased TGFβ expression in tumor cells
contributes to cancer progression and provides new avenues for novel anticancer therapeutic designs.
Rigorous investigation leading

to the identification of the other

components of the mRNP complex binding the BAT element and the underlying
mechanism of translational activation of the identified transcripts following TGFβ
stimulation will surely be one of the avenues of future research. Future work will
also delve into the iterative cycle of system modeling, hypothesis generation and
systematic experimentation that will address if this hnRNP E1 posttranscriptional
regulon is involved in TGFβ-induced EMT and metastatic progression of tumors
and delineate how each transcript contributes to the EMT process.
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Even though research spanning over the last two decades has candidly
outlined details of TGFβ signaling pathway in physiological and pathological
conditions, much remains to be elucidated about the precise mechanisms of its
deregulation in different forms and stages of cancer. Furthermore, detailed
mechanistic explanation is still unavailable for the apparent paradoxical
observation that TGFβ can induce cell cycle arrest and cytoskeletal alterations in
the same cell. Answers to these questions will undoubtedly lead not only to
many interesting and surprising observations that reveal additional regulatory
complexities, but hopefully lead to the development of TGFβ-dependent anticancer therapies. Right now we are at a very exciting phase having all the tools
for this next phase of transition into translational research.
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Figure 5.1: BAT element: battling TGFβ-induced EMT along with hnRNP E1.
As shown in Chapters II, III, and IV a novel post-transcriptional pathway exists by
which TGFβ through hnRNP E1 phosphorylation modulates expression of EMTspecific proteins and EMT itself through regulatory BAT elements in transcripts
required for EMT.
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